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Abstract

STAT3 IN THE REGULATION OF BROWN ADIPOCYTE DIFFERENTIATION
Marc Cantwell, B.S.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2018
Advisor: Andrew C. Larner, M.D., Ph.D.
Professor, Department of Biochemistry and Molecular Biology
Thermogenic fat is a promising target for new therapies in diabetes and obesity.
Understanding how thermogenic fat develops is important to develop rational strategies to treat
obesity. Previously, we have shown that Tyk2 and STAT3, part of the JAK-STAT pathway, are
necessary for proper development of classical brown fat. Using primary preadipocytes isolated
from newborn mice we demonstrate that STAT3 is required for differentiation and robust
expression of Uncoupling Protein 1. We also confirm that STAT3 is necessary during the early
induction stage of differentiation and is dispensable during the later terminal differentiation
stage. Without STAT3, the brown preadipocytes have increased apoptosis early in the terminal
differentiation phase. We also show that the block in differentiation is caused by an inability of
STAT3 knockouts to down regulate β-catenin by the end of the induction phase. Application of
Wnt/β-catenin inhibitors or knockdown of β-catenin during the induction phase is sufficient to
fully rescue differentiation of brown adipocytes from the Myf5+ lineage, including reduction in

apoptosis, restoration of histone acetylation in the UCP1 promoter and enhancer regions, and full
restoration of the expression of brown fat genes. Finally, we show that in the beige lineage,
STAT3 is also necessary during the induction phase and can be rescued by Wnt/β-catenin
inhibitors, although the rescue is not as robust as it is in the Myf5+ lineage.
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Chapter 1: Introduction

Obesity is a medical condition that occurs when an individual has increased adipose
tissue mass compared to amounts that are considered normal based on the individuals age,
height, and gender. The prevalence of obesity has increased in the past forty years in the United
States: fully one-third of the adult population is obese (1). The major impact of obesity is due to
the comorbidities that develop in parallel; there are currently more than thirty medical conditions
that are associated with obesity (2). Consequently, obesity is associated with an increase in
overall mortality. Obesity together with its comorbidities are estimated to cost the US population
190 billion dollars per year, or approximately two thousand dollars per year per person (3). Due
to this burden on the American healthcare system as well as the increased morbidity and
mortality associated with obesity, new therapies and treatments are needed to reverse the weight
gain trends of the last forty years.
One approach that has attracted much attention over the past few years has been to
increase the mass of a specialized type of adipose tissue called Brown Adipose Tissue (BAT).
BAT is a thermogenic tissue; its purpose is to generate heat through the metabolism of lipids in
order to maintain optimal body temperature (4). There are ample amounts of this tissue present in
animals such as rodents; however, it used to be thought that in humans BAT is only present in
newborn infants and regressed to undetectable levels in adulthood. That understanding has been
overturned in the last decade by findings that adults do in fact possess significant depots of BAT
(5). The presence of BAT in adults has ignited interest in understanding the mechanisms of
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development of this tissue in order to translate this knowledge into clinical applications towards
obesity treatment.
The purpose of this dissertation is to explore the role of a transcription factor called
Signal Transducer and Activator of Transcription 3 (STAT3) in the regulation of the
development of BAT. The following section gives an overview on the epidemiology, etiology,
and associated comorbidities of obesity. Next, a review of BAT tissue function, how it may
prevent or diminish obesity and related metabolic diseases gleaned from in-vivo studies in
rodents, and the human relevance of this tissue. Afterwards, a brief background on the genes
currently known to impact the development of adipose tissue, a process referred to as
adipogenesis, will be given. The JAK/STAT pathway will be introduced afterwards, with
emphasis on what is already known about this pathway’s role in regulating adipogenesis. Finally,
the Wnt signaling pathway and its role in suppressing adipogenesis will be introduced—this
dissertation presents evidence that this pathway is negatively regulated by STAT3 during brown
adipocyte development.
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1.1 Epidemiology, Etiology, and Associated Comorbidities of Obesity
Epidemiology of Obesity. Obesity in adults is defined by the World Health Organization
and the National Institutes of Health as having a body mass index (BMI) greater than 30kg/m2
(6, 7). Surveys of obesity have been conducted in the United States for years—the most
prominent survey is the National Health and Nutrition Examination Survey (NHANES),
conducted by the U.S. Centers for Disease Control and Prevention (CDC) (8). NHANES utilizes
a mobile examination center where physical assessments can be made using standardized
protocols, rather than relying on self-reported data (9). The data from NHANES has shown that
since the 1980s, the rates of obesity have been increasing in both men and women. In 1980, the
prevalence of obesity in the U.S. population was approximately 10% for men and 15% for
women, but by 2014, the prevalence was 35% among men and 40% among women (9, 10).
Geographically, the rates of obesity are not evenly distributed across the United States: southern
states like Mississippi have a higher prevalence of obesity compared to west coast and
northeastern states (11). Worldwide, while there is variation from country to country, there has
been an increasing trend from 29/30% (men/women) in 1980 to 37/38% in 2013 (12).
For children, the prevalence of obesity has also been increasing over time, which is a
particularly grave problem as risks of developing comorbidities and reduced life expectancy are
increased the longer an individual is obese (2). Obesity is defined in children in the US as being
above the 95th percentile in the CDC BMI-for-age growth charts; for adolescents the prevalence
of obesity increased from 10% in 1994 to 20% in 2014 (13). Worldwide, the prevalence in 2013
was 24% in developed countries and 13% in developing countries (12).
Etiology of Obesity. Fundamentally, obesity is caused by a mismatch between caloric
intake and total daily energy expenditure (TDEE). When the daily caloric content of food
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exceeds the TDEE, the excess calories are stored as fat. The adipose tissue expands, both through
hypertrophy and hyperplasia (14). However, while thermodynamics is the fundamental cause for
increase adipose tissue mass, how this mismatch is established is more complex and involves
interactions between genes and the environment.
Genetic disorders that display a Mendelian pattern of inheritance are rare contributors to
the etiology of obesity; however, they illuminate the control these genes have over regulation of
appetite. These disorders can be classified as monogenic, where the primary finding is obesity, or
syndromic, where obesity is one clinical finding among a constellation of findings (and generally
includes some form of mental retardation) (2, 15). The most common monogenic disorders
involve disturbances to the Leptin signaling pathway and the Melanocortin 4 receptor, while the
most common syndromic disorder is Prader-Willi Syndrome (15).
Leptin is a hormone that is produced in adipose tissue and produces satiety when it binds
to its cognate receptor on the POMC and NPY/AGRP neurons in the arcuate nucleus of the
hypothalamus (Figure 1.1) (16). Loss of either leptin or the leptin receptor results in hyperphagia
and, subsequently, obesity (17). Individuals that are leptin deficient can receive subcutaneous
injection of leptin that results in dramatic reduction in appetite and weight (18). Mouse models of
leptin deficiency (ob/ob) and leptin receptor deficiency (db/db) exist and are popular for studies
of obesity and Type II Diabetes (T2D) (19).
Mutations in the Melanocortin 4 receptor (MCR4) are the most common form of
monogenic obesity (20). MCR4 is involved in the same neural regulation of appetite pathway as
leptin and leptin receptor (21). In fact, leptin signaling increases production of the proopiomelanocortin (POMC) gene (22). POMC is a prohormone that is converted into multiple
products, the most relevant product here being α-Melanocyte Stimulating Hormone (αMSH).
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αMSH is released by the POMC neuron and binds to the MC4R on the melanin-concentrating
hormone (MCH) neuron, where it acts to decrease firing of this neuron. Administration of MCR4
agonists in rodents leads to a decrease in food intake (23).
Overall, monogenic and syndromic causes of obesity make up a small percentage of the
obese cohort, therefore most genetic contributors to obesity are polygenic in origin, i.e., Single
Nucleotide Polymorphisms (SNPs) that an individual possesses each contribute and interact with
each other to modify an individuals risk of developing obesity. Genome Wide Association
Studies (GWAS) have been conducted in an attempt to identify common polymorphisms that
increase and individual’s risk of developing obesity or associated comorbidities (i.e. T2D) (24).
The most studied allele that increases risk of obesity and T2D is the fat mass and obesity
associated gene (FTO) (25). Individuals who are homozygous for the most common obesitycausing variant weigh 3kg more and had an elevated risk of developing obesity 1.67 fold above
those not carrying the risk variant (26). In the last few years, the function of the FTO allele and
how it may contribute to obesity has been discovered (see section I.II-Human Studies of BAT).
Common environmental contributors to obesity include an increase in the sedentary
lifestyle, reduced physical activity including exercise, and increased availability of low cost, high
caloric density foods (27). Numerous studies in adults and children have documented the
increase risk that a sedentary lifestyle paired with a diet that is considered unhealthy (e.g. high in
processed sugars) is positively correlated with obesity (28-31). Lastly, another potentially major
environmental contributor to obesity risk is currently under intense study: the gut microbiome.
Analyzing the microbiome of the gut has begun to show associations with obesity and metabolic
disorders, but causality has yet to be established (32-34).
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Associated Comorbidities. Diabetes is a disease where the plasma levels of glucose are elevated
(hyperglycemia). The major hormone that regulates plasma glucose levels is insulin. Insulin
promotes the uptake of glucose into tissues such as adipose and skeletal muscle tissue. Chronic
elevation of plasma glucose levels leads to pathologies in the kidneys, eyes, peripheral nervous
system, and the cardiovascular system (35). There are two major types of Diabetes: Type I and
Type II. Type I is defined by the lack of insulin production and is an autoimmune disorder
against the cells of the endocrine pancreas that produce insulin (the pancreatic β cells) (36). Type
II diabetes is defined by a systemic reduction in insulin responsiveness (insulin insensitivity); the
pancreas is still able to produce insulin in Type II diabetes, at least in the initial stages of the
disease (37). Adipose tissue contributes to the regulation of plasma glucose levels via release of
hormones that regulates insulin sensitivity in other tissues, while also increasing the uptake of
glucose with the insulin-regulated GLUT4 glucose transporter (38, 39). However, in obese
individuals, the adipose tissue releases elevated levels of free fatty acids and pro-inflammatory
cytokines like tumor necrosis factor alpha (TNFα), which act locally and systemically to reduce
responsiveness to insulin (40-43). Therefore, obese individuals have a higher risk of developing
diabetes than their lean counterparts.
Increased adiposity is correlated with increased risk of 13 types of cancers (44). While
casual mechanisms are still unclear, it is likely that the combination of increased hormones and
inflammatory cytokines coupled with a conducive microenvironment increases risk of tumor
initiation and progression (45, 46).
Obesity increased the risk of developing hypertension and increases risks of stroke,
atherosclerosis, and myocardial infarction (47). In women, obesity can exacerbate Polycystic
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Ovarian Syndrome, a disorder that involves increased androgen production and insulin
insensitivity (48). Additionally, obese women have a higher risk of ovulatory infertility (49, 50).
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Figure 1.1- Basic Neural Regulation of Appetite
Leptin is a hormone produced by the adipose tissue and circulates to the arcuate nucleus of the
hypothalamus where it binds to the leptin receptor on the POMC neuron, resulting in the
increased probability of an action potential. The POMC neuron releases αMSH into the synaptic
cleft between the POMC and MCH neuron. The MCH neuron contains the MC4R and binding of
αMSH reduces the likelihood of the MCH firing an action potential. AGRP neuron produces the
Agouti Related Protein, which is an antagonist of the MC4R. Adapted from (51), copyright
license: 4282461312035.
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1.2 BAT Function and Human Relevance
Comparison of BAT and WAT. There are two general types of adipose tissue present in
humans: Brown Adipose Tissue and White Adipose Tissue (WAT). Each type of adipose tissue
serves a specific purpose. BAT and WAT are so named because of the coloration of the tissue at
the gross level. BAT is brown in coloration due to large amounts of mitochondria present in the
adipocytes. The large numbers of mitochondria are necessary for BAT to serve its function (vide
infra). In contrast, WAT contains relatively fewer mitochondria compared to BAT, and as a
result is paler in color. Histologically, WAT and BAT can be easily discriminated based upon the
lipid droplet morphology present in the cell (Figure 1.2). WAT contains a single large lipid
droplet, while BAT contains multiple smaller lipid droplets (with the mitochondria interspersed
between the smaller lipid droplets). Additionally, BAT is more highly innervated by the
sympathetic nervous system and more vascularized than WAT. Table 1.1 summarizes the basic
characteristics of these two adipose tissues.
The anatomic locations of the two adipose tissues are also different. WAT is generally
distributed across the body with large depots in the hypodermis of the skin and within the
abdominal cavity. In contrast, BAT is more restricted in its locations; BAT is present in the
human in supraclavicular, perirenal, and paravertebral depots. In the rodent, BAT is also present
in axillary and interscapular depots.
WAT’s major role is to store energy in the form of triacylglycerides (TAG) and to
distribute the energy to the rest of the organism during periods of negative caloric balance. When
fasting, lower levels of blood glucose stimulate epinephrine release from the adrenal glands. The
epinephrine signals onto beta-adrenergic receptors on the adipocyte that result in activation of a
lipase called Hormone Sensitive Lipase (HSL). HSL liberates free fatty acids (FFA) and glycerol
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from the TAGs and secrete the FFAs into the blood for distribution to other tissues (mainly the
liver and skeletal muscle), and secretes the glycerol to serve as a gluconeogenic substrate in the
liver. Activation of HSL is opposed by insulin, which levels rise in response to higher blood
glucose levels.
Additionally, WAT functions as an endocrine organ; the hormones they secrete are
termed “adipokines”. Two major adipokines produced by WAT are Leptin and Adiponectin.
Adiponectin serves to modulate glucose and fatty acid modulation; treatment with exogenous
adiponectin has been found to reduce serum glucose levels and increase insulin sensitivity (52,
53). The levels of leptin in the serum are positively correlated to the total amount of adipose
tissue in the organism, therefore, leptin signals to the hypothalamus the status of the fat reserves
(17). Interestingly, leptin signals through a Type I cytokine receptor, and the downstream STAT
that mediates this signaling is STAT3 (54). Deletion of STAT3 using a Nestin Cre, which targets
both neuronal and glial cells, resulted in mice that were hyperphagic, obese, and diabetic, which
is phenotypically similar to the ob/ob and db/db mice (55). Additionally, the mice were unable to
maintain their core body temperature upon cold challenge. Histology revealed disorganized BAT
that the authors believed was due to the reduced sympathetic output to the BAT.
In contrast, BAT does not store TAGs for distribution to other tissues during periods of
starvation, rather, it is a thermoregulatory tissue; BAT metabolizes TAGs to produce heat in
order to maintain optimal body temperature. BAT accomplishes its thermoregulatory function
through an inner mitochondrial transmembrane protein called Uncoupling Protein 1 (UCP1).
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Figure 1.2- Histology of BAT and WAT
BAT and WAT can be discriminated by the lipid droplet morphology. BAT contains a
centralized nucleus in addition to multiple small lipid droplets, which, when looked at through
electron microscopy, are surrounded by large numbers of mitochondria (left). In contrast, WAT
contains one single large lipid droplet with a nucleus relegated to the periphery of the cell (right).
Additionally, the white adipocytes are larger in size compared to brown adipocytes. The brown
coloration of the BAT is due to immunohistochemical staining for UCP1, the functional protein
of BAT. Scale bar = 40 µm. Adapted from (56), copyright license: 4277360251493.
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Characteristics
Function

Macroscopic Features

Microscopic Features

Molecular Markers

WAT
Energy Storage, Lipolysis and
Secretion of FFAs/glycerol,
Secretion of hormones such as
Leptin and Adiponectin
Locations: Subcutaneous,
abdominal, retroperitoneal,
perirenal, gonadal
Color: White; yellow to offwhite hue
Adequate Vascularization
(++)
Sympathetic (++)
Tissue Organization: Small
lobules densely packed
Cell Architecture: Unilocular
lipid droplet occupying 90%
of volume, variable size and
shape (25-200µm)
Nucleus: Peripherally located
Mitochondria: Few
High presence of other cell
types (fibroblasts and immune
cells)
UCP1 (-), UCP2 (++)
β3 adrenoreceptor (+)
PGC1α (+)
PRDM16 (-)
CIDEA (-)
Leptin (+++)

Table 1.1- Summary of WAT and BAT Characteristics
Modified from (57); Copyright License: 4278460310955
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BAT
Non-shivering Thermogenesis,
Low Secretory Ability
Interscapular (rodents),
paravertebral, axillary, and
periadrenal
Color: Brown; light pink to
dark red
Highly Vascularized (++++)
Sympathetic (++++)
Tissue Organization: lobular
organization with gland-like
structure
Cell Architecture:
Multilocular lipid droplets,
polygonal and small (1560µm)
Nucleus: Centrally located
Mitochondria: Abundant
Low presence of other cell
types
UCP1 (++++)
β3 adrenoreceptor (+++)
PGC1α (+++)
PRDM16 (+++)
CIDEA (+++)
Leptin (+)

The Mitochondria Structure and Function. The mitochondrion is a membrane-bound
organelle that is important in regulating metabolism and generating adenosine triphosphate
(ATP). The mitochondrion contains two membranes: an inner and outer membrane. These
membranes separate the internal components of the mitochondrion into two compartments: the
intermembrane space, located between the inner and outer membrane, and the matrix. The inner
mitochondrial membrane is uniquely structured to be highly impermeant to many small
molecules, and as a result, many different types of solute carriers are needed to transport
molecules across this membrane. The impermeance of the membrane is necessary for its function
in generating ATP. Complexes of proteins, collectively called the Electron Transport Chain
(ETC), form a series of oxidation/reduction (redox) reactions that take electrons from the
substrates Nicotinamide adenine dinucleotide (NADH) and Flavin Adenine Dinucleotide
(FADH2), and ultimately pass the electrons to the terminal acceptor, molecular oxygen (Figure
1.3). These complexes couple the energy released in the redox reactions to pump hydrogen ions
from the matrix into the intermembrane space against an electrochemical gradient. This
hydrogen ion gradient is a form of potential energy and generates a membrane potential across
the inner mitochondrial membrane. ATP Synthase, another integral membrane protein of the
inner membrane, utilizes the electrochemical gradient in order to produce ATP. The Hydrogen
ions flow down the electrochemical gradient through a pore in the ATP Synthase, and the energy
released by the ions moving down this gradient is coupled to the formation of a phosphodiester
bond between adenosine diphosphate (ADP) and inorganic phosphate.
The Uncoupling Protein 1. UCP1 is a member of the Uncoupling proteins family, which
is a subfamily of the Solute Carrier family (SLC). There are five members of the Uncoupling
protein family in mammals: UCP1, UCP2, UCP3, UCP4, and UCP5. Each member has a
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different tissue distribution: UCP1 is restricted solely to BAT; UCP2 is more widespread, but
with abundant expression in skeletal muscle; UCP4 and UCP5 are expressed in the nervous
system (58).
All members of the family are localized to the inner mitochondrial membrane and
function as a hydrogen ion transporter. In this regard they are similar to ATP synthase; however,
the energy released by the flow of hydrogen ions down the electrochemical gradient is not
coupled to ATP synthesis. As a result, the energy released is in the form of heat rather than
chemical work. Therefore, the uncoupling proteins are so called because they “uncouple”
respiration (the redox reactions of the ETC), from ATP synthesis. The increased permeability of
the inner membrane to hydrogen ions results in the collapse of the mitochondrial membrane
potential; this reduction in membrane potential can be utilized as a functional output of UCP1
function.
Under resting conditions, UCP1 has low conductance to hydrogen ions. Binding of long
chain FFAs to UCP1 results in increased conductance (59). As a result, only when the cells are
stimulated to increase lipolysis does UCP1 become maximally activated. This activation occurs
when the organism senses its core body temperature decreasing; increased sympathetic output to
BAT results in release of norepinephrine and subsequent binding to the β3-adrenergic receptor
(60). The β3 adrenergic receptor is a G-protein coupled receptor (GPCR) that is associated with
adenylyl cyclase, an enzyme that produces 3',5' cyclic adenosine monophosphate (cAMP). Upon
stimulation of the β3-adrenergic receptor cAMP levels rise in the cell, which leads to activation
of a protein kinase called Protein Kinase A (PKA). PKA subsequently phosphorylates HSL and
this leads to liberation of FFAs for use in binding and activating UCP1 as well as serving as
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substrates for β-oxidation to maintain ATP levels. This regulation assures that UCP1 is properly
activated when environmental conditions require thermogenesis to hypothermia.
While all members of the uncoupling family release the energy of the hydrogen ion
gradient as heat, only UCP1 appears to function solely to generate heat for maintaining body
temperature. While the primary function of the other UCPs are not as well characterized as
UCP1, it appears they may primarily serve to reduce production of Reactive Oxygen Species
(ROS) produced by the ETC, as well as play a role in regulating insulin secretion from the beta
cells of the pancreas (58, 61, 62).
The factors that directly regulate UCP1 will be discussed in detail in section III of this
chapter.
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Figure 1.3- The Electron Transport Chain
NADH and FADH2 are products of glycolysis and the citric acid cycle. They are carriers of
electrons and are oxidized by Complex I (NADH) and Complex II (FADH2). As the electrons
are passed in a series of redox reactions to the terminal electron acceptor molecular oxygen,
hydrogen ions are pumped from the matrix to the intermembrane space. This creates an
electrochemical gradient that is harnessed to produce ATP by ATP Synthase. Adapted from (63),
copyright license: 4277400364416.

18

BAT in the prevention of weight gain and Insulin Resistance. Whether the mass of BAT
can actually affect whole-body energy balance and metabolic performance is an important
question if this tissue should be realistically considered as part of future therapy in humans.
Stanford et al. showed that increasing BAT in rodents through surgical transplantation can
mitigate the effects of a western style high-fat diet (HFD) (64). In this study, male mice were
assigned to 100mg BAT transplant, 100mg WAT transplant, or sham treatment. The mice
receiving the BAT transplant were highly resistant to weight gain on a HFD. Additionally, the
BAT implanted mice had improved glucose tolerance up to twelve weeks post-implantation, as
well as more rapid glucose clearing. Interestingly, this enhanced glucose clearing was due to
increased glucose uptake in many endogenous tissues, including visceral WAT and heart. This
increased glucose uptake was due to increased circulating levels of fibroblast growth factor 21
(FGF21), and Interleukin-6 (IL-6) that was secreted by the transplanted tissue. FGF21 is a
growth factor that has been shown to affect glucose levels and insulin sensitivity (65). IL-6 is
important to mention here, as this cytokine signals through STAT3 (see section IV in this
chapter). Indeed, if the transplanted BAT was IL6-/-, the levels of circulating FGF21 decreased,
indicating that paracrine action of IL-6 in BAT drives FGF21 expression and secretion. Further
studies in mice utilizing BAT transplantation have shown that increasing BAT mass can partially
revert obesity in Leptin receptor mice (Ob/Ob strain), reduce PCOS signs in rats, reduce
atherosclerosis in a high cholesterol diet mouse model, and improve glucose tolerance
independent of insulin in a Type I diabetic model (66-69).
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Human Studies of BAT. While studies in rodent models of BAT on obesity and metabolic
performance are promising, the relevance of BAT on affecting those metabolic parameters in
humans is of intense interest. Adult humans possess significant stores of BAT, which can be
visualized using 18F-fluorodeoxyglucose positron-emission tomography (18F-FDG PET) and
computed tomography (70). Under thermoneutral conditions (defined as an ambient temperature
that can sustain core body temperature under basal metabolic conditions, 22°C for humans), PET
activity of BAT was negligible, but when the volunteers were submitted to cold exposure (16°C),
PET activity increased in the supraclavicular and paraspinal regions. Interestingly, there is a
negative correlation of BAT activity with BMI and body fat percentage. The supraclavicular,
paraspinal, and periadrenal regions that are PET active under cold exposure are true BAT; biopsy
of these locations reveals fat cells that have the histological hallmark of multilocular lipid
droplets and positive staining for UCP1 (Figure 1.4). Interestingly, one study identified that
there may be a sex difference in brown adipose tissue mass, with women potentially possessing
more BAT than men (5).
The stores of BAT in humans may be of clinical consequence to obesity. Claussnitzer et
al. reported a remarkable connection between obesity genetics and BAT development (5). They
showed that the FTO allele, an allele that has been found to have a moderate association with
adiposity and T2D, led to an increase in two developmental factors IRX3 and IRX5. These two
factors repress the thermogenic program and promote differentiation into WAT instead. The
authors knocked out IRX3 in adipose tissue in mice, which led to reduced body weight and
increased energy expenditure that was not due to any increased physical activity. Knock out in
human preadipocytes with the FTO allele restored the browning potential of the cells. Mutating
the FTO allele to the non-risk variant also restored the ability of the preadipocytes to express the
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thermogenic program. They further determined that the mutation in the FTO allele destroys a
binding site for a repressor called ARID5B in an enhancer region for the IRX3 and IRX5 genes.
This is some of the first evidence that altering the ability of preadipocytes to express the
thermogenic program can have important consequences for the development of obesity and
diabetes.
Now that there is evidence that BAT is present in humans and that aberrant development
of BAT can lead to increased risk of obesity and diabetes, the next step is to determine if it is
possible to manipulate the amount of BAT tissue in humans; if this is possible then it is a proofof-principle that BAT can be a viable therapeutic target. Since BAT is a thermoregulatory tissue
that is stimulated under conditions of suboptimal environmental temperature, the easiest- and
safest- way to attempt to induce increases in BAT mass is to expose humans to mild cold stress
environments. Lee et al. took five volunteers and subjected them to mild overnight cold stress
(71). In this crossover study, the volunteers were housed overnight in a controlled environment
where they were exposed to cyclical changes in temperature: either a mild cold stress of 19°C or
warm conditions (27°C). They found that just sleeping in a cold environment for one month was
enough to increase BAT mass by 42 percent. The participants were able to go about their lives
normally during the day, but the time spent in the cold environment overnight was enough to
induce the recruitment of additional BAT mass. Additionally, return to the warm environment
for one month was enough to reduce the BAT mass that was accumulated prior. This was one of
the first pieces of evidence that BAT mass is plastic in humans and that interventions can indeed
alter the amount of tissue in a human.
Altering the temperature can certainly increase BAT in man, but it is not a therapeutic
option to house patients overnight in a climate-controlled chamber. Thus, pharmacological
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methods are needed. As stated above, BAT and BAT precursors carry a unique isoform of a betaadrenergic receptor: the β3- adrenergic receptor. Specific β3 agonists exist, and treatment of cell
cultures or administration to experimental animals in vivo can induce expression of the
thermogenic program and UCP1 (72). Additionally, the β3 receptor is restricted to mostly
adipose tissue and bladder wall muscle (73). In the bladder, β3 agonism results in relaxation of
the bladder wall muscle (the detrusor muscle), and as a result, there is a β3 agonist that is
currently FDA approved drug for treatment of overactive bladder (74). Because this drug is
already approved, testing for a new application in increasing BAT mass would be easier. Cypess
et al. recruited healthy volunteers to take this β3 agonist, trade name Mirabegron, to see if they
could induce BAT mass/activity in a reversible manner (75). They observed that one 200mg dose
was sufficient to increase BAT activity as measured by 18F-FDG PET, increased glucose uptake
in the BAT, and led to an increase of the resting metabolic rate by 200 kcal. However,
administration of this drug currently has some drawbacks. While Mirabegron is a specific β3
agonist, the dose given to the participants led to considerable side effects of increased heart rate
and blood pressure. More specific agonists that are less likely to affect the cardiovascular system
are thus needed.
Two types of BAT: Myf5+ and Myf5-. In recent years the brown fat field has identified
distinct developmental lineages of UCP1+ positive adipose tissue. Classically, studies in rodents
have focused on the BAT found in the interscapular fat pad. This was termed “classical” brown
fat. This lineage of BAT is termed Myf5+ brown fat, and these cells share an immediate
precursor with skeletal muscle (76). However, in the rodent, another depot of UCP1+ brown
adipocytes can be found in the subcutaneous fat pads in the inguinal region. These cells are not
related to the Myf5 lineage and are thus called Myf5-/beige/brite cells (77). While both types of
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cells express UCP1, each differ in molecular markers they express (78). Additionally, these two
types of BAT have important functional differences. Myf5+ brown fat contains large amount of
mitochondria and highly express UCP1 in the absence of stimulation, however, beige cells under
resting conditions do not express the thermogenic program and have few mitochondria- only
under sympathetic stimulation do the beige cells activate the thermogenic program and express
UCP1 at similar levels to My5+ brown fat (77). This can be recapitulated in-vitro: Myf5+
preadipocytes will differentiate and express the thermogenic program after induction with no
additional stimuli, while beige preadipocytes must be stimulated with either β-adrenergic
agonists or PPARγ agonists (i.e. thiazolidinediones) after induction in order to express UCP1
(79, 80). In humans, clonal analysis has identified that the majority of the deposits that contain
UCP1 are from a beige origin (77, 81). Therefore, while understanding the development of BAT
using Myf5+ precursors is a valuable tool and can provide key insights into beige development,
studies in beige cell development are more likely to have human relevance.
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Figure 1.4- Immunofluorescence staining of human fat tissue biopsies
Human fat tissue was obtained at the supraclavicular (top row), periadrenal (middle row), or
subcutaneous (bottom row) sites and were stained for UCP1 (green fluorescence, left column),
and Cytochrome C Oxidase (marker of mitochondrial mass, red fluorescence, middle column).
The rightmost column is a superimposed image. Both the supraclavicular and periadrenal sites
contain UCP1+ fat tissue, while subcutaneous tissue is negative for UCP1 expression. Adapted
from (82), copyright license: 4278520154370.
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1.3 Genes Involved in Adipogenesis and Browning
Studies using cell lines of preadipocytes and transgenic animals have determined
much of the core program of adipogenesis that is shared by all types of adipose tissue.
Additionally, factors that specifically regulate the thermogenic program and UCP1 expression
have been identified. Review of the identity and function of these genes as well as the temporal
order in which these genes operate is provided here. A general schematic of the genetic program
of brown adipogenesis is presented in Figure 1.5.
The CCAAT/Enhancer Binding Proteins (CEBP). The CEBP transcription factor family
contains six members: CEBPα, CEBPβ, CEBPδ, CEBPε, and CEBPζ. They are members of the
basic-leucine zipper (bZIP) transcription factor family (83). Of the six members, CEBPα,
CEBPβ, and CEBPδ are important for adipogenesis in-vitro and in-vivo, and CEBPσ is directly
regulated by STAT3 (84, 85). When the preadipocytes are stimulated to differentiate in culture,
CEBPβ and CEBPδ are one of the first genes to be induced; they reach peak expression within 4
hours of stimulation (86). In-vitro, CEBPβ is sufficient for differentiation, while CEBPδ is
dispensable (87). However, in-vivo loss of CEBPβ or CEBPδ alone does not lead to a significant
reduction in adipose mass, but the CEBPβ/CEBPδ double knockout does result in significant loss
of adipose mass, suggesting that in-vivo these two transcription factors are redundant (88).
CEBPβ and CEBPδ’s major targets are the next two transcription factors necessary for
differentiation, CEBPα and Peroxisome Proliferator Activated Receptor Gamma (PPARγ) (89,
90). CEBPβ also cooperatively binds to PPARγ to regulate genes involved in the terminal
differentiation program. During the first 48 hours of differentiation in-vitro, the cells re-enter the
cell cycle and proliferate during the phase called the “Mitotic Clonal Expansion” (MCE) (91).
CEBPα is anti-proliferative and ends the MCE by increasing expression and stability of the cell
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cycle inhibitor, p21 (92). Additionally, CEBPα regulates some of the common terminal markers
of mature adipocytes like leptin, fatty acid binding protein 4 (FABP4/aP2), and GLUT4 (93, 94).
In-vivo, CEBPα is absolutely necessary; knockout animals have reduced lipid droplet size and
BAT has reduced UCP1 expression (95).
Peroxisome Proliferator Activated Receptor Gamma (PPARγ). The PPAR family is a
member of the nuclear receptor superfamily, and they function by heterodimerizing with the
retinoid X receptor (RXR) and binding to peroxisome proliferator response elements (PPREs) in
the promoters of target genes (96). PPARγ is considered the “master regulator” of adipogenesis,
because no other factor has been identified that can compensate for loss of PPARγ (97). There
are two isoforms of PPARγ: PPARγ1 and PPARγ2 (98). PPARγ1 is more widely distributed
across different tissues, but PPARγ2 is restricted to adipose tissue. PPARγ2 levels begin to
increase around day 4 after stimulation to differentiate, and is regulated by CEBPα, while
PPARγ1 is constitutively expressed throughout the entire differentiation time course (99).
PPARγ works cooperatively with CEBPα and CEBPβ to regulate the genes expressed during the
terminal differentiation phase of adipocytes (100). PPARγ, along with its co-factor Peroxisome
Proliferator Activated Receptor Gamma Co-Activator 1 Alpha (PGC1α), directly regulate
transcription of the UCP1 gene (101). Both PPARγ1 and PPARγ2 can induce the adipocyte
program, however, PPARγ2 can induce adipogenesis under reduced ligand concentrations
compared to PPARγ1 (102). In-vitro, PPARy2 is sufficient to induce differentiation of
fibroblasts into adipocytes, indicating that PPARγ may also have a role in determining cell fate
(103). The thiazolidinediones, a class of anti-diabetic drugs, are agonists for PPARγ, and can be
used in cell culture to increase expression of UCP1, especially in beige cells (77, 80).
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Peroxisome Proliferator Activated Receptor Gamma Co-Activator 1 Alpha (PGC1α).
PGC1α regulates mitochondrial biogenesis and increases the cells ability to generate energy
(104). PGC1α accomplishes these by co-activating Nuclear Respiratory Factors 1 and 2 (NRF1
and NRF2), two transcriptions factors that regulate nuclear-encoded components of the ETC and
mitochondrial transcription factor A (Tfam), which regulates mitochondrial DNA transcription
and replication (105). It is expressed in tissues that have high rates of oxidative phosphorylation
such as cardiac muscle, Type I (oxidative, slow-twitch) skeletal muscle, and BAT (106). PGC1α
increases UCP1 expression by augmenting the transcriptional abilities of PPARγ and thyroid
hormone receptor (104). PGC1α also regulates the expression of cell death-inducing DFFA-like
effector (CIDEA), a negative regulator of UCP1 function (106, 107).
PR Domain Containing 16 (PRDM16). PRDM16 was the first transcription factor
identified that specifically controls the determination of BAT; when expressed in WAT
progenitors, it is able to induce the thermogenic program, in part by upregulating PGC1α (108,
109). Conversely, deleting PRDM16 in adipose tissue using and adiponectin promoter driven Cre
leads to an inability of subcutaneous fat to beige and insulin resistance (110). In Myf5+
progenitor cells, expression of PRDM16 promotes the differentiation into BAT, while ablation of
PRDM16 promotes differentiation into skeletal muscle (111). PRDM16 interacts with Med1,
part of the mediator complex, and recruits the complex to enhancer regions of thermogenic genes
(112, 113). Interestingly, BAT specific knockout of PRDM16 does not affect the embryonic
development of BAT tissue, however, it is required for maintenance of the BAT phenotype as
the mice age (114).
Early B-cell Factor 2 (EBF2). PPARγ is present in both WAT and BAT and directly
regulates UCP1 expression, yet in WAT UCP1 is undetectable. Therefore, it was postulated that
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a factor exists in classical BAT and beige cells that allows selective recruitment of PPARγ to
thermogenic genes. The EBF binding motif was found near PPARγ binding sites in BAT specific
genes and subsequent ChIPseq experiments revealed that EBF2 binds to these motifs and recruits
PPARγ to these sites in part by interacting with the BAF chromatin remodeling complex to
control access to the promoters (115, 116). Knockout of EBF2 either in-vitro or in-vivo resulted
in loss of the thermogenic program with no effects on the general adipocyte program.
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Figure 1.5- Schematic representation of the major genes involved in general- and brownadipogenesis
Left Column: Myf5- adipocyte lineage (which includes beige cells). Right Column: Myf5+
lineage containing the classical brown fat cell. Adapted from (57), copyright license
4301971047874.
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1.4 The JAK/STAT Pathway and its Known Roles in Adipogenesis
Introduction of the JAK/STAT Pathway. The Janus Kinase (JAK)-Signal Transducer and
Activator of Transcription (STAT) pathway was initially identified in the 1990s as the mediator
of interferon signaling (117). Subsequently, this pathway has been implicated in a variety of
other processes such as development (especially in the hematopoietic system), cell growth,
immune responses, and cancer (118).
The JAKs are a family of tyrosine kinases consisting of four members: JAK1, JAK2,
JAK3, and Tyrosine Kinase 2 (Tyk2). These kinases have a FERM domain that is necessary for
interaction with their cognate cytokine receptors and two tyrosine kinase domains, JH1 and JH2;
however, JH2 is a pseudo kinase domain that lacks an ATP binding site, yet is necessary for full
functionality of JAKs (Figure 1.6) (119). JAK1, JAK2, and Tyk2 are widely distributed across
different tissues, whereas JAK3 is mostly restricted to the hematopoietic lineage (120).
There are seven known STATs in mammals: STAT1, STAT2, STAT3, STAT4,
STAT5A, STAT5B, and STAT6 (121). The structures of the different STATs are mostly
conserved, with some important differences that will not be addressed here. For STAT3, the
structural schematic is found in Figure 1.7. STAT3 contains an N-terminal domain, which is
used to form STAT3 tetramers, following by a coiled-coiled domain which is involved in
protein-protein interactions with other transcription factors and regulators (122). The DNA
binding domain contains residues that recognize specific DNA sequences found in the promoters
of STAT3 regulated genes. The SH2 domain is involved in recognizing phosphotyrosine residues
and is used to dock to the cytoplasmic tails of cytokine receptors, as well as dimerize with other
STATs. C-terminal to the SH2 domain is a tyrosine residue that is phosphorylated by the JAKs
(Y705). In STAT3, there exists two forms owing to differential splicing: STAT3α and STAT3β.
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These isoforms differ in the possession of a C-terminal Transactivation Domain (TAD), which is
present in the alpha form, but is absent in the beta form. The TAD contains a serine site that is
phosphorylated by members of the MAPK and mTOR families (123, 124). The TAD enhances
the transcriptional regulatory ability of STAT3 through its protein-protein interactions with other
members of the transcriptional machinery such as CBP/p300 (125).
The JAKs associate with cytokine receptors, which are single transmembrane proteins
with an extracellular ligand binding domain and an intracellular cytoplasmic tail that serves as a
docking site for JAKs and STATs (126). Different cytokine receptors recruit different JAKs and
STATs, allowing for increased complexity with a small set of components (127). Cytokine
receptors are not active on their own, however, cytokines bind two cytokine receptors and bring
them in close apposition. The JAKs associated with each cytokine receptor phosphorylate
themselves, leading to maximal kinase activation, as well as phosphorylating the cytoplasmic tail
of the receptor. These phosphotyrosine resides in the cytoplasmic tail serve as docking sites for
the STATs. The STATs dock at the cytokine receptor through their SH2 domain, where they are
subsequently tyrosine phosphorylated by the JAKs. The STATs dissociate from the receptor and
then either homo- or hetero-dimerize through binding of the phosphotyrosine residue present in
the other STAT through their SH2 domains. Once the STATs dimerize, they are able to transport
to the nucleus and bind to conserved DNA binding sequences where they can exert their gene
regulatory effects (128). A schematic of this classical pathway is shown in Figure 1.8.
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Figure 1.6- Schematic of the JAK family of tyrosine kinases
Adapted from (129), copyright license 4301961262534.

32

Figure 1.7- Schematic of STAT3
N= N-terminal Domain, CC= Coiled-Coiled Domain, DNA = DNA binding Domain, LK=
Linker Domain, SH2= SH2 Domain, Y= JAK phosphorylated tyrosine residue, TA =
Transactivation Domain. Adapted from (122), copyright license 4301951395247.
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Figure 1.8- Schematic of the canonical JAK/STAT pathway
Cytokine binding to cytokine receptors activate the associated JAKs, which tyrosine
phosphorylate the cytoplasmic tail of the receptor, creating a docking site for STATs. STATs
dock at the receptor and are phosphorylated by the JAKs. The STATs dimerize and translocate to
the nucleus where they bind to DNA and affect transcription. The pathway is tightly regulated
through the actions of other proteins, such as Suppressor of Cytokine Signaling (SOCS), protein
tyrosine phosphatases (PTP) and Protein Inhibitor of Activated STAT (PIAS). Adapted from
(130). Copyright license: 4318860682296.
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STAT3 in Adipogenesis. The majority of studies to date looking into the role of STAT3 in
adipogenesis have utilized the 3T3-L1 cell line, an immortalized mouse cell line that is
committed to differentiating into white adipose cells. The earliest studies indicated that STAT3
was necessary for proliferation of the preadipocytes to confluence and possibly needed for the
proliferation of the preadipocytes during the MCE phase of differentiation (131). The authors
noted that during induction STAT3 remained tyrosine phosphorylated for up to 3 days, which
coincides with the MCE and early terminal differentiation phase. Using EMSA assays, STAT3
was bound to the DNA during the proliferation to confluence and to a minor extent during the
MCE, but no binding was evident during the terminal differentiation phase. Thus, the authors
concluded that STAT3 was only required for the proliferation of cells to confluence and possibly
during the MCE, but is likely not required in the terminal differentiation phase.
Additional evidence of the importance of STAT3 for adipogenesis comes from a study of
Protein Inhibitor of Activated STAT3 (PIAS3), a protein that binds to STAT3’s DNA binding
domain, which blocks STAT3s transcriptional activity. Overexpression of PIAS3 in
preadipocytes led to reduced mRNA expression of PPARγ and CEBPα, as well as the terminal
markers aP2 and Adiponectin (132). Additionally, the authors found that ob/ob mice had natural
overexpression of PIAS3 in WAT.
After establishing STAT3’s importance in adipogenesis, other groups set out to determine
what STAT3 was regulating during adipogenesis and what signaling molecules drive STAT3
activity. Leptin and LIF are two cytokines that bind to receptors that recruit STAT3. Leptin
treatment in rat preadipocytes enhanced adipogenesis, while LIF had no major effect on
adipogenesis per se, but did reduce the level of lipid accumulation in the mature adipocytes (133,
134). Midkine, also known as neurite growth-promoting factor 2 (NEGF2), was identified as an
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autocrine/paracrine factor that is released upon induction of differentiation in 3T3-L1 cells and is
the factor responsible for STAT3’s tyrosine phosphorylation during the induction phase of
adipogenesis; blocking antibodies to midkine reduced STAT3 phosphorylation, reduced the
MCE, and reduced adipogenesis (135). How midkine signaling leads to tyrosine phosphorylation
is unknown, as the receptor for midkine is considered to be a tyrosine phosphatase (136).
The mechanism of STAT3 in the regulation of adipogenesis is not well characterized.
STAT3 was shown to transcriptionally regulate CEBPβ, one of the first genes induced in
adipogenesis (137). The authors also showed that STAT3 binds to the distal region of the
promoter for CEBPβ. Additional research indicated that STAT3 acts upstream of PPARγ;
chemical inhibition of STAT3 or knockdown using siRNA reduced adipogenesis, but could be
rescued by using a PPARγ agonist (138).
In immortalized brown adipocytes, we previously published that STAT3 was downstream
of Tyk2 and interacts and stabilizes PRDM16 (139). Moreover, expression of a constitutively
activated STAT3 (STAT3C) in Tyk2-/- was sufficient to rescue brown adipogenesis. Finally,
STAT3C expression in the BAT of Tyk2-/- animals can restore the expression of brown fat
markers such as UCP1 and CIDEA.
In-vivo studies of STAT3 in the regulation of adipogenesis are lacking. Total STAT3
knockout causes embryonic lethality in mice, so tissue specific knockouts are required. An aP2
promoter driven Cre mouse was used to generate adipose tissue that lacks STAT3. The mice
have increased weight and increased fat mass due to hypertrophy of the WAT- the hypertrophy
was likely due to impaired lipolysis in response to leptin (140). However, aP2 is not specific to
adipose tissue and is expressed relatively late in the development of adipose tissue and therefore
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this mouse model may not capture the effects of STAT3 on differentiation of adipose tissue, but
rather is a model of STAT3’s role in the function of mature adipocytes (141).
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1.5 The Wnt Pathway and its Role in Suppressing Adipogenesis
The Canonical Wnt/β-Catenin Signaling Pathway. The Wnt pathway is important for
normal development of all metazoans; this pathway is responsible for diverse functions such as
establishment of cell polarity in epithelium, cell fate, and maintenance of pluripotency of stem
cells (142, 143).
The Wnt pathway contains 19 different secreted Wnt ligands (144). These are
glycoproteins that all share conserved serine residues, which are acylated by the endoplasmic
reticulum enzyme Porcupine (PORCN) (145). This acylation is necessary for secretion of Wnt
ligands and for optimal binding of the ligands to their receptors (146). Once the Wnt ligands
have been acylated, they are recognized by the carrier protein Wntless, which ferries the ligands
through the Golgi and to the extracellular surface of the plasma membrane (147). Once released
to the extracellular environment, they bind to their receptors, which is composed of two proteins
called Frizzled (of which there are a number of different members) and Lipoprotein ReceptorRelated Protein 5 and 6 (LRP5/6) (148). While there are a number of downstream effectors in the
Wnt pathway, the most common is the canonical pathway involving β-catenin.
β-Catenin is a multifunctional protein. It is both a transcription factor and a component of
cadherin junctions (149). Figure 1.9 details how β-Catenin is regulated as a transcription factor.
In the absence of Wnt ligand, β-catenin is marked for proteasomal degradation. A priming
phosphorylation at serine 45 by Casein Kinase 1α allows β-catenin to be recognized by a
destruction complex composed of the scaffold protein Axin2, Adenomatous Polyposis Coli
(APC), and Glycogen Synthase Kinase 3β (GSK3β) (150). GSK3β phosphorylates β-catenin at
serines 33 and 37; these serine sites serve as recognition sequences for an E3 Ubiquitin Ligase
called βTrcp. Once ubiquitinated, β-catenin is rapidly degraded by the proteasome. However, if
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Wnt ligand is present, it signals through the Frizzled/LRP receptor, which allows recruitment of
Axin to bind to LRP (151). The binding of the destruction complex to the receptor inactivates the
destruction complex, allowing β-catenin to accumulate. Accumulating free cytosolic β-catenin is
then available for transport to the nucleus, where it can bind to many partners to affect its nuclear
function, but its most well defined partner is TCF (152). Additionally, β-Catenin turnover can be
fined tuned by regulating different components of the destruction complex. For example, Axin2
stability can be altered by tankyrases 1 and 2 (153). Tankyrases are poly-ADP-Ribosylating
enzymes; when Axin2 is ADP-Ribosylated it is marked for proteasomal degradation.
The Wnt Pathway in the Suppression of Adipogenesis. The Wnt pathway is well studied
in the context of adipogenesis, and it is firmly established to be a negative regulator of
adipogenesis. Treatment with Wnt1 or introduction of a stabilized form of beta-catenin is
sufficient to suppress adipogenesis in 3T3-L1 cells (154). Specifically, this was due to a decrease
in expression of PPARγ and CEBPα, and adipogenesis could be rescued if either of these
transcription factors were overexpressed. While Wnt1 can suppress adipogenesis, it is likely that
Wnt10b is responsible for this repression as it is highly expressed in preadipocytes and as the
cells differentiate levels of this ligand diminish (155). In brown fat, Wnt signaling reduces
PGC1α during differentiation, which is an important co-factor involved in the expression of
UCP1 (156). Additionally, mature adipocytes treated with Wnt10a have suppressed UCP1
protein levels and in-vivo can convert brown adipocytes to a more white-like phenotype (157).
Non-canonical Wnt pathways can also modulate adipogenesis. Wnt5b antagonizes the
canonical pathway through increased GSK3β-mediated degradation activity and can partially
restore adipogenesis with cells that are co-treated with Wnt3a (158). Wnts 2 and 11, part of the
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Calcium/Calmodulin/Calcineurin non-canonical Wnt pathway, decrease adipogenesis in the 3T3L1 cell line (159).
Normally, Wnt signaling is reduced during differentiation through silencing of Wnt
ligand genes through the actions of the metyltransferase EZH2 tri-methylating Histone H3 K27
in the Wnt ligand promoters (160). The silencing of Wnt ligands should have the effect of
reducing β-catenin, since without that signaling, the GSK3β destruction complex will
phosphorylate β-catenin to tag it for destruction by the proteasome. Further regulation of βcatenin comes through cross-talk with PPARγ (161). Activation of PPARγ with exogenous
ligands leads to reduced β-catenin stability, possibly through a direct interaction between PPARγ
and β-catenin (162).
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Figure 1.9- The canonical Wnt/β-catenin pathway
Left Panel: When Wnt ligand is absent, the Axin2/APC/GSK3β destruction complex is able to
bind and phosphorylate β-catenin, which is a recognition mark for the E3 Ubiquitin Ligase
βTRCP. β-Catenin is degraded by the proteasome and as a result does not transit to the nucleus.
TCF1 interacts with Groucho (GRG), which represses Wnt regulated genes. Right Panel: When
Wnt ligand is present, the Axin2/APC/GSK3β destruction complex is inhibited and β-Catenin is
left unphosphorylated, causing its levels to build up and eventually translocate to the nucleus. βCatenin displaces Groucho and binds with TCF1, leading to upregulation of Wnt driven genes.
Adapted from (163), Copyright license 4302051187472.
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1.6 Dissertation Rationale and Objectives
Previously, we observed that Tyk2 KO brown adipocytes do not differentiate and can be
rescued with constitutively active STAT3 (139). How STAT3 was able to rescue the Tyk2 KO
was not investigated, and the mechanism of STAT3 in adipogenesis has been poorly defined.
This objective of this dissertation is to answer three questions, with each building upon the
previous: 1) Is STAT3 needed for differentiation of primary brown adipocytes? 2) When is
STAT3 required for differentiation- is it always required to maintain a brown adipocyte or is
there a distinct period in development where STAT3 acts and then is no longer necessary? 3)
What is STAT3 regulating during differentiation- does it regulate another known pathway that
either positively or negatively regulates adipogenesis?
This dissertation provides evidence to all three questions posed. We show that STAT3 is
indeed necessary for primary brown fat differentiation, that is only required during the induction
phase, and that it functions to suppress Wnt/β-catenin signaling during the induction phase,
likely through suppression of Wnt ligand expression.
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Chapter 2: Materials and Methods
2.1 Generation of Mice
All mice were bred and maintained in the animal facility at MCV/VCU in accordance with the
Institutional Animal Care and Use Committee (IACUC). Mice containing STAT3 with flanking
Lox-P sites (Flox) were obtained from Jackson Laboratory- strain #016923. These mice were
crossed with mice containing a ubiquitously expressed Tamoxifen induced Cre Recombinase in
the ROSA locus (Jackson Laboratory)-strain #008463. The offspring were bred until they were
homozygous for both the floxed STAT3 allele and Tamoxifen-inducible Cre Recombinase allele;
these mice served as founders for the colony. Floxed Tyk2 mice were a gift from Brigit Strobel.
These mice were crossed with the Tamoxifen-Inducible Cre Recombinase mice until mice that
were homozygous for floxed Tyk2 and Tamoxifen Cre Recombinase. All mice were genotyped
to confirm possession of the desired alleles.
2.2 Mouse Genotyping
The mice were genotyped using a modified HotSHOT genomic DNA isolation protocol. A 13mm tail snip was incubated with 75µL alkaline lysis buffer (25mM NaOH, 0.2mM EDTA, pH
12.0) at 95°C for 1 hour. After allowing the sample to cool to room temperature, 75µL of
neutralization buffer (40mM Tris-HCl, pH 4.0) was added and the samples were briefly
vortexed. The PCR reaction contained the following: 5µL of Genomic DNA sample, 12.5µL of
2x GoTaq Hot Start Green Master Mix (Promega), 2.5µL of a mixture containing the primers
each at a concentration of 2.5µM, 0.625µL of 20mg/mL Bovine Serum Albumin (Sigma-
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Aldrich), and 4.38µL of dH2O. The following PCR conditions were used: 1) 95°C for 5 minutes,
2) 95°C for 30 seconds, 55°C for 30 seconds, 72°C for 30 seconds, repeated for 30 cycles, 3)
72°C for 10 minutes. The PCR products were run on a 1% Agarose (Fisher)/TBE (National
Diagnostics) gel with 0.5µg/mL Ethidium Bromide (Fisher) at 100V for 1 hour. The sequences
for the genotyping primers can be found in table 2.1.
2.3 Isolation of Primary Brown Preadipocytes
For Myf5+ Preadipocytes, one to three day-old pups were used to isolate primary preadipocytes.
The pups were sacrificed by decapitation and the interscapular fat pad was harvested. Fat pads
from different mice were pooled together during isolation; each pool is considered a biological
replicate. Each pool contained a variable number of mice, but the minimum was three. The fat
pads were minced and placed in isolation buffer (123mM NaCl, 5mM KCl, 1.3mM CaCl2, 5mM
Glucose, 100mM HEPES, 4g/100mL Bovine Serum Albumin, Antibiotics/Antimycotics)
containing 1.5mg/mL of Collagenase A (Roche) and incubated for 40 minutes at 37°C with
rocking. After the incubation period, the digestion was passed through a sterile 70µm nylon filter
(Fisher) and the resulting filtrate was centrifuged at 500g for 5 minutes at room temperature. The
supernatant was removed and the cell pellet (containing a mixture of preadipocytes and blood
cells) was resuspended in 1mL of PBS for every fat pad in the pool (e.g. 5 fat pads processed5mL of PBS resuspension). The cells were plated onto dishes such that the starting density would
allow the cells to reach confluence between Day 5 and 7 after isolation; the volumes of the cell
resuspension plated for each type of dish were determined empirically and are found in table 2.2.
The cells were plated into DMEM (GIBCO) growth media containing 4.5g/L Glucose, 5nM
Insulin (Sigma-Aldrich), Antibiotics/Antimycotics (GIBCO), and 20% FBS (Foundation Brand,
Gemini Bio Products). Additionally, the media either contained 1µM of 4-OH Tamoxifen
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(Sigma-Aldrich) to delete STAT3 or the ethanol vehicle. The cells were incubated with either
Tamoxifen or vehicle for two days after isolation, and then were washed in PBS and fresh
growth media was added. The media was changed every two days until confluence. Once the cell
cultures reached confluence, the cells were induced to differentiate.
For Myf5- (beige) preadipocytes, one-month-old mice were sacrificed and the inguinal fat pads
were harvested and processed as above.
2.4 Induction of Differentiation
Once the cells reached confluence, they were induced to differentiate. The growth media was
replaced with DMEM (GIBCO) differentiation media containing 4.5g/L Glucose, 20nM Insulin,
1nM T3, 10% FBS, and Antibiotics/Antimycotics. Additionally, the media contained a cocktail
of 500µM IBMX, 125µM Indomethacin, 2mg/mL Dexamethasone, and 1µM Rosiglitazone
(Sigma-Aldrich). The cells were incubated with the cocktail for 48 hours, and then aspirated and
replaced with the base differentiation media lacking the cocktail. The cells were allowed to
differentiate for five days after removal of the cocktail, with the media being replaced every two
days. For Myf5- preadipocytes, 1µM Rosiglitazone was kept in the media for the full seven days
of differentiation. Figure 2.1 is an illustration of the in-vitro time course that contains the date
labeling used throughout the rest of the dissertation.
2.5 Temporal Knockout Studies
1µM 4-OH Tamoxifen was added for 48 hours on either Day 2 or Day 5 post-addition of
induction cocktail. The media was removed and the cells were washed with PBS and replaced
with fresh differentiation media.
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2.6 In-Vitro Treatments
Unless otherwise stated, all treatments are applied for the full seven days of differentiation
starting from the addition of the induction cocktail. Fresh inhibitor was added with each media
change. Appropriate vehicles were used as controls. The following chemicals were used: IWP2
(Porcupine Inhibitor, 1µM, Selleckchem), C59-Wnt (Porcupine Inhibitor, 1µM, ApexBio),
IWR1-endo (β-Catenin Inhibitor, 5µM, Selleckchem), FK506 (Calcineurin Inhibitor, 10ng/mL,
Cayman Chemical), XAV939 (Tankyarase Inhibitor, 1µM, Cayman Chemical), CHIR99021
(GSK3β Inhibitor, 10µM, Cayman Chemical), PD0325901 (MEK Inhibitor, 10µM, SigmaAldrich), Isoproterenol (β-adrenoreceptor agonist, 10uM, Sigma-Aldrich), FCCP (chemical
uncoupler, 10µM, Cayman Chemical), SAG (Smoothened Agonist/Hedgehog activator, 100nM,
Calbiochem), DAPT (γ-Secretase Inhibitor/Notch Inhibitor, 5µM, Tocris), MG-132 (proteasome
inhibitor, 10µM, Sigma-Aldrich), Cryptotanshinone (STAT3 inhibitor, 10µM, Selleckchem),
Ruxolitinib (pan-JAK inhibitor, 2µM, Selleckchem), H2O2 (to induce apoptosis, 500µM, SigmaAldrich).
2.7 siRNA Transfection
siGenome SMARTpool control #1 and mouse specific β-catenin were purchased from
Dharmacon and resuspended in siRNA buffer to 5µM. Primary cells were grown in 6 well plates.
48 hours before induction, the cells were washed three times with PBS and replaced with 1.6mL
of antibiotic free primary media. The transfection cocktail was created as follows: for every well
transfected, solution A contained 10µL of the siRNA and 190µL serum free media and solution
B contained 4µL of Dharmafect Solution #1 and 196µL serum free media. After incubation for 5
minutes, solutions A and B were combined and incubated an additional 20 minutes at room
temperature. 400µL of the transfection cocktail was added to each well and was left on the cells
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for 48 hours. After the transfection, the cells were washed with PBS and then were directly
induced to differentiate, or harvested in Trizol for mRNA analysis of the knockdown efficiency.
2.8 SDS-PAGE and Immunoblotting
Cells were washed in PBS and lysed on ice with 1x RIPA buffer containing protease and
phosphatase inhibitors. The samples were incubated on ice for 30 minutes and then centrifuged
for 10 minutes at 10,000g at 4°C. The supernatant was removed in such as way to minimize
carry over of lipids from the differentiated cells. Protein concentration was measured using the
BCA assay (Pierce). The lysates were combined with 4x Laemmli sample buffer (Bio-Rad)
containing 1mM β-Mercaptoethanol. The samples were incubated at 65°C for 10 minutes and
separated using SDS-PAGE electrophoresis using Tris-Glycine gels. Gels were transferred to
PVDF membranes (Millipore) using a semi-dry transfer system (Bio-Rad). The membranes were
blocked with either 5% milk or 5% BSA in 1x TBS + 0.05% Tween 20 (TBST) for 1 hour at
room temperature. The membranes were incubated with primary antibodies in either milk or
BSA TBST overnight at 4°C with gentle rocking. The membranes were washed and incubated
with 1:5000 of anti-rabbit or anti-mouse HRP secondary antibody (GE Healthcare, #NA934 and
#NA931) for 1 hour at room temperature with rocking. After washing, the membranes were
incubated with either Amersham ECL (GE Healthcare), or ECL2 Reagent (ThermoFisher) and
developed using CL-X Exposure Film (ThermoFisher). Films were scanned using an Epson
Expression 1680 scanner in transmitted light mode at 16-bit greyscale with 300dpi resolution.
Densitometry was performed using ImageJ software (National Institutes of Health). TATA
Binding Protein (TBP) was used as the loading control. The primary antibodies used can be
found in table 2.3.
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2.9 RNA Extraction and Real-Time PCR
RNA was obtained using the Trizol method (Invitrogen). The RNA pellet was dissolved in
DEPC-treated water (Sigma-Aldrich) and quantitated using absorbance at 260nm on a Nanodrop
200 (Thermo Fisher). 2µg of RNA was used in the first strand synthesis reaction. The High
Capacity RNA-to-cDNA Kit (Applied Biosystems) was used according to manufacturer
recommendations. The 20µL reaction volume was diluted with 380µL of dH2O. 5µL of the
cDNAs were combined with SYBR Green (SensiMix SYBR & Fluorescein Kit, Bioline), and
with 250nM each of forward and reverse primers (table 2.4). The real-time PCRs were run on a
CFX96 Real-Time PCR Detection System (Bio-Rad) using the following thermocycling
conditions: 1) 95°C 10 minutes, 1x 2) 95°C 15 seconds, 57°C 15 seconds, 72°C 15 seconds, 40x.
A melt curve analysis was included at the end of each run. No-transcript controls (NTC) were
used to assess for genomic DNA contamination; the sample was considered pure if the NTCs
amplified above 35 cycles or more than 6 cycles above the sample target (~100 fold less
expression). The data was analyzed using the ΔΔCt method.
2.10 Oil-Red O Staining
Fully differentiated Brown Adipocytes (Day 7 after induction) were fixed in 10% formaldehyde
for 1 hour at room temperature. The fixed cells were washed with PBS and then incubated with
60% isopropanol for 5 minutes. Stock Oil Red O stain (3mg/mL, 100% isopropanol) was diluted
using 3 parts of the stock stain to 2 parts dH2O and filtered through a Whatman paper filter. The
filtered stain was applied to the cells for 1 hour at room temperature. The stain was removed and
the plate was washed several times with water. The plates were imaged using an AxioObserver
A1 microscope with a 10x/0.12 Ph1 lens and AxioCam MRc5 camera (Zeiss). Plates were
quantitated for the area of the plate occupied by the stain by the threshold/analyze particles
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function in Image J (version 1.49, NIH). At least three random fields were imaged per sample.
Whole plates were scanned with an Epson Expression 1680 scanner in reflective mode in 24 bit
color at 300dpi resolution.
2.11 Proliferation Studies
For analysis of proliferation prior to confluence, cells were labeled on the day of isolation using
the Tag-IT Violet™ Cell Proliferation Dye (Biolegend). Briefly, the primary cell pellet was
resuspended in PBS containing 5µM of the dye and incubated for 20 minutes at 37°C with
shaking. The cells were plated except for a sample that was retained for initial fluorescent
measurement. Cells were fixed using 4% Formaldehyde for 10 minutes at room temperature and
analyzed on the BD LSRFortessa-X20 system using the following laser and filter configuration:
405nm with BP 450/50. The data was analyzed using FCSExpress software. For proliferation
during and after induction, confluent cells were washed with PBS and were incubated with 5µM
of Tag-IT in HBSS with Calcium and Magnesium for 20 minutes at 37°C. The HBSS was
replaced with media and control WT and KO cells were harvested and fixed as above to establish
Day 0 fluorescence, while the rest of the cells were induced to differentiate.
2.12 Chromatin Immunoprecipation Assays
Two confluent ten-centimeter dishes were used per sample. Cells were fixed for 10 minutes at
room temperature with 1% formaldehyde, then 5 minutes of 150 mM glycine, and washed with
PBS. The cells were incubated in Farnham lysis buffer (85mM KCl, 0.5% NP-40, 5mM PIPES
pH 8.0) for 15 minutes on ice and spun down at 500g for 10 minutes to collect nuclei. The nuclei
were lysed in sonication buffer (50 mM Tris-HCl pH 8.0, 10 mM EDTA, 1% SDS) and
sonicated using a bioruptorpico sonicator (Diagenode) for 5 cycles of 30sec ON/30sec OFF. The
sonicated lysate was diluted 1:10 in dilution buffer (20 mM Tris-HCl pH 8.0, 150 mM NaCl, 2
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mM EDTA, 0.1% SDS, 1.0% Triton X-100) and manufacturer recommended amounts of
antibodies were added and incubated overnight at 4 degrees. Non-specific matched species IgG
was used as a control. 30 µL of 1% BSA blocked magnetic Protein A/G beads (Thermoscientific) were added for 2 hours at 4 degrees then precipitated using a magnet and washed
twice with dilution buffer and once with high salt wash (20 mM Tris-HCl pH 8.0, 500 mM NaCl,
2 mM EDTA, 0.1% SDS, 1.0% Triton X-100). The DNA was eluted using 1% SDS/ 0.1M
Sodium Bicarbonate Buffer and de-crosslinked by heating overnight at 65 degrees. RNase A
(ThermoScientific) and Proteinase K (New England Biolabs) were added, respectfully, for 1 hour
each and the DNA was isolated using Qiaquick PCR Purification Kit (Qiagen). The real-time
quantitative polymerase chain reaction (qPCR) reaction was performed on the CFX96 Real-Time
PCR Detection System (Bio-Rad, Hercules, CA, USA), using the manufacturer
recommendations from the SensiMix SYBR and Fluorescein Kit (Bioline). 5% of the input was
saved for the calculations. The sequences for the ChIP primers can be found in Table 2.5.
2.13 Mitochondrial Isolation
Two 15cm dishes of cells were used per sample. Adherent cells were washed with PBS,
trypsinized, and collected in ice-cold media containing serum. Cells were spun down at 500g for
5 minutes at 4°C and the pellets were washed 1x with PBS. Cells were spun down again at 500g
and the supernatant was aspirated. The cells were resuspended in 1mL of sucrose buffer (10mM
HEPES, pH 7.4, 250mM sucrose, 1mM EDTA, protease and phosphatase inhibitors) and
incubated in ice for 10 minutes. Cells were then added to a metal douncer and cells were
homogenized by hand on ice until approximately 90% of cells were broken (verified by trypan
blue). The homogenate was spun down for 5 minutes at 800g at 4°C to pellet nuclei and intact
cells. The supernatant was collected and spun down for 10 minutes at 8800g at 4°C to pellet
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crude mitochondria. The supernatant was collected and labeled as the cytosolic fraction and spun
an additional 10 minutes at 10,000g to remove any remaining organelle components. The
supernatant was collected and frozen at -80°C for further analysis. The crude mitochondrial
pellet was resuspended in 490µL sucrose buffer and 10µL of a 5mg/mL solution of trypsin was
added to the sample. Samples for rotated for 10 minutes at 4°C after which 500µL of a 5% BSA
solution was added to stop the trypsinization. Samples were rotated for an additional minute and
then spun down at 10000g for 10 minutes at 4°C. The supernatant was aspirated (including the
digested material around the mitochondria) and the pellet was washed 2x with 500µL of the
sucrose buffer. After the final wash, the pellets were resuspended in an appropriate volume of
sucrose buffer and stored at -80°C for further analysis.
2.14 Apoptosis Assays
Cells were incubated with AlexaFluor 488 annexin V/Propidium Iodidie Kit (ThermoFisher)
according to manufacturer protocols. The BD FACSCanto II analyzer was used for data
acquisition. The following lasers and filter configurations were used: 488nm with BP 530/30 and
BP 610/20. The data was analyzed using FCSExpress software. Cells incubated with 500µM
H2O2 for 5 hours at 37°C was used as a positive control
2.15 In-vivo Beiging Studies
8 week old- Floxed STAT3-Tamoxifen Inducible Cre animals were orally gavaged once per day
for 5 days with 5mg/20g body weight Tamoxifen (Cayman Chemicals). The mice were allowed
to rest for 1 month. Afterwards, the mice were injected intraperitoneally (I.P.) once a day for
seven days with either CL316,243 (Sigma-Aldrich) at a dose of 1mg/kg or an equivalent volume
of PBS. The mice were then sacrificed and the inguinal fat pads were harvested and lysed in
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RIPA buffer containing protease and phosphatase inhibitors. The lysates were stored at -80°C for
further analysis.
2.16 Statistical Analysis
Data is presented as mean ± SEM, except for qPCR data which is expressed as mean ± SD.
Statistical Analysis was performed using Prism 7 (GraphPad) using the statistical tests indicated
in figure legends. A p-value <0.05 was considered significant. N=3 unless otherwise indicated.
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Figure 2.1- In-Vitro time course
Growth/Proliferation Phase is from isolation of the primary cells to confluence, which generally
takes 7 days. When the cells reach confluence they are induced to differentiate, which lasts for
48 hours (D0-D2); the induction phase is also called the MCE. D2-D7 is the Terminal
Differentiation Phase.
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Gene

Primer Sequences
Forward:

Notes
Floxed Allele: 600bp

TTGACCTGTGCTCCTACAAAAA WT Allele: 400bp
Flox STAT3
Reverse:
CCCTAGATTAGGCCAGCACA
Forward:

Cre Allele: 825bp

AAAGTCGCTCTGAGTTGTTAT

WT Allele: 603bp

Reverse:
Tamoxifen Cre
GGAGCGGGAGAAATGGATATG
Mutant Reverse:
CCTGATCCTGGCAATTTCG
Table 2.1- Genotyping Primers
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Plate

Volume (µL)

35mm

150

60mm

350

10cm

750

24 well

75

12 well

150

6 well

250

Table 2.2- Plating Volumes for Primary Cells
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Target
UCP1
TBP
STAT3
pSTAT3 Y705
pSTAT3 S727
β-Catenin
PPARγ
FABP4 (aP2)
CEBPα
STAT1
NDUFA9
Tubulin
GAPDH

Company, catalog #, lot #
R&D Biosystems, MAB6158,
CCNV0116081
Cell Signaling Technology,
3544, 1
Cell Signaling Technology,
9139, 8
Cell Signaling Technology,
9145, 31
Cell Signaling Technology,
9134, 21
Cell Signaling Technology,
8480, 5
Cell Signaling Technology,
2443, 3
Cell Signaling Technology,
3544, 2
Cell Signaling Technology,
8178, 3
BD Biosciences
Santa Cruz Biotechnology
Sigma-Aldrich,
T8328
Cell Signaling Technology,
5174

Table 2.3- Antibodies for Immunoblotting
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Species
Mouse
Rabbit
Mouse
Rabbit
Rabbit
Rabbit
Rabbit
Rabbit
Rabbit

Mouse
Rabbit

Target
18S
Adiponectin
aP2
Axin2
CEBPα
CIDEA
Dkk1
EBF2
PGC1α
PPARα
PPARγ
PRDM16
Tbp
UCP1
Wnt1
Wnt10b
Wnt3a
β-Catenin

Sequence
F: CCATCCAATCGGTAGTAGCG
R: GTAACCCGTTGAACCCCATT
F: TGACGACACCAAAAGGGCTC
R: CACAAGTTCCCTTGGGTGGA
F: TGAAATCACCGCAGACGACA
R: ACACATTCCACCACCAGCTT
F: CAGCCCAAGAACCGGGAAAT
R: AGCCTCCTCTCTTTTACAGCA
F: AATGGCAGTGTGCACGTCTA
R: CCCCAGCCGTTAGTGAAGAG
F: GGCCGTGTTAAGGAATCTGC
R: GTATGTGCCCGCATAGACCA
F: ACACCAAAGGACAAGAAGGCT
R: CTTGGTGCACACCTGACCTT
F: GCTGCGGGAACCGGAACGAGA
R: ACACGACCTGGAACCGCCTCA
F: TGAAAAAGCTTGACTGGCGTC
R: AGCAGCACACTCTATGTCACTC
F: TGTGAACTGACGTTTGTGGC
R: CCACAGAGCGCTAAGCTGT
F: CTGTGAGACCAACAGCCTGAC
R: TGGTTCACCGCTTCTTTCAA
F: CAGCACGGTGAAGCCATTC
R: GCGTGCATCCGCTTGTG
F: AGTGCCCAGCATCACTATTTCA
R: GTGGAAGGCTGTTGTTCTGG
F: CACGGGGACCTACAATGCTT
R: TAGGGGTCGTCCCTTTCCAA
F: GATGGTGGGGCATCGTGAAC
R: GTTCTGTCGGATCAGTCGCC
F: TGTGGATCCTGCACCTGAAC
R: TAGAGCCCGACTGAACAAAGC
F: GGGTGTCAAAGCGGGCATCCA
R: CCCGGGTGGCTTTGTCCAGAA
F: CCATTGTACGCACCATGCAG
R: CCACTGGTGACCCAAGCATT

Table 2.4- Primers for Real-Time qPCR
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Target
Actin Promoter
PRDM16 Promoter
UCP1 Enhancer
UCP1 Proximal Promoter

Sequence
F: AAATGCTGCACTGTGCGGCG
R: AGGCAACTTTCGGAACGGCG
F: GAGGGAATCTATAGGGAGGACTCTCT
R: AATCCGGTTAAAACAGCAATCC
F: CTCCTCTACAGCGTCACAGAGG
R: AGTCTGAGGAAAGGGTTGA
F: CCCACTAGCAGCTCTTTGGA
R: CTGTGGAGCAGCTCAAAGGT

Table 2.5- Primers for Chromatin Immunoprecipitation
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Chapter 3: Results
The data presented are in Myf5+ cells isolated from the interscapular region, unless otherwise
indicated.
3.1 STAT3 is Phosphorylated During the Induction Period
To begin our study of STAT3 in brown adipose tissue development, we wanted to
determine when STAT3 functions during differentiation. We took wild type primary cells,
induced them to differentiate, and collected samples at different time points for analysis of total
STAT3 and phosphorylated forms of STAT3. As seen in Figure 3.1, STAT3 is basally
phosphorylated before addition of the induction cocktail, is rapidly dephosphorylated upon
addition of the cocktail, then returns to basal levels for 24 hours, and still is detectable by 48
hours. Additionally, STAT3 serine phosphorylation rapidly increases upon addition of the
induction cocktail and is elevated for 24 hours. This time course is in agreement with previous
studies of STAT3 in the 3T3-L1 cell line (135, 164). Interestingly, total STAT3 amounts
decrease after the induction period is complete and remain low throughout the rest of the
terminal differentiation phase. These findings suggests that STAT3 is likely required during the
induction phase (D0-D2) only.
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Figure 3.1- STAT3 levels during in-vitro differentiation
A representative immunoblot of whole cell extracts from wild type interscapular SVF. Time 0
are cells before induction, all time points are measured post-addition of induction cocktail.
Tubulin is used as a loading control. N=3.
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3.2 Inhibition of STAT3 Blocks Differentiation of Brown Adipocytes
To continue analysis of the role of STAT3 in the development of brown adipocytes,
STAT3 was inhibited throughout the entire differentiation time course from addition of induction
cocktail. We choose cryptotanshinone, a natural product inhibitor of STAT3 that prevents
dimerization by binding the SH2 domain, as it was well tolerated by the cells for the entire time
course. We treated the cells with 10µM cryptotanshinone and after 6 days, samples were
collected samples for RT-qPCR. As shown in Figure 3.2, treatment with the STAT3 inhibitor
reduces expression of both brown fat specific and general fat markers.
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Figure 3.2- Inhibition of STAT3 suppresses expression of terminal adipogenic markers
Expression of brown fat specific and general adipocyte markers measured by RT-qPCR. N=2,
data are expressed as mean ± SD. Tbp was used as a loading control.
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3.3 Inhibition of STAT3 During the Induction Period Only Blocks Differentiation
Since STAT3 is phosphorylated only during the induction period, we hypothesized that
STAT3 is only required for differentiation during this period and that inhibition during the
terminal differentiation phase (D2-D7) would have no effect. We used cryptotanshinone, a
natural product inhibitor of STAT3 that prevents dimerization by binding to the SH2 domain, to
investigate the temporal requirement for STAT3 (165). In Figure 3.3, 10µM of cryptotanshinone
was added in 24-hour windows during the differentiation time course. To control for media
changes, every sample was given fresh media every 24 hours and either the inhibitor or the
DMSO vehicle. As expected, treatment with cryptotanshinone during the 24-hour windows that
correspond to the induction period suppressed expression of UCP1, especially during the first 24
hours, but treatment during any 24-hour window after induction had no effect on UCP1. This is
further evidence that STAT3 is only required during the differentiation period. However,
cryptotanshinone is an SH2 domain inhibitor, and it likely has off-target effects, such as
inhibition of STAT5, which is also important for adipogenesis (166).
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Figure 3.3- Inhibition of STAT3 during the induction phase reduces UCP1 expression
Representative immunoblot from Day 7 whole cell extracts of cells treated with the STAT3
inhibitor for the 24-hour window indicated above each lane. N=3. Tbp was used as a loading
control.
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3.4 Generation of a Floxed-STAT3, Tamoxifen Inducible Cre Leads to Efficient Total
Knockout
The analysis thus of STAT3 in brown adipogenesis have utilized wild type brown
preadipocytes and chemical inhibition of STAT3. However, in order to determine the mechanism
of STAT3, a reproducible STAT3 Knockout (KO) primary cell system was needed. Therefore,
mice that are homozygous for floxed STAT3 and a Tamoxifen- Inducible Cre Recombinase were
generated for the study. The mice were viable and no defects were observed throughout the
mouse lifespan. In Figure 3.4, harvested cells that were exposed to 1µM of 4-OH Tamoxifen for
48 hours have no detectable STAT3 at Day 0, when the cells are confluent but have yet to be
induced. Interestingly, there are also reduced PRDM16, PPARγ, and CEBPδ levels before the
start of differentiation. The reduced levels of PRDM16 are in agreement with our prior published
work (139).
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Figure 3.4- Treatment with 4-OH Tamoxifen efficiently reduces STAT3 and loss of STAT3
reduces levels of transcription factors important for differentiation.
Immunoblot of three biological replicates of STAT3 WT and KO preadipocytes on Day 0.
GAPDH was used as a loading control.
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3.5 Deletion of STAT3 Does Not Affect Proliferation of Preadipocytes in the Growth Phase
It has previously been reported that knockdown of STAT3 in the 3T3-L1 line reduces the
proliferation rate of the cells compared to control during the growth phase to confluence (131).
Any differences in proliferation during growth to confluence must be assessed as the cells are not
primed to differentiate before they reach confluence and contact-growth inhibit each other, and
any reduction in differentiation of the STAT3 KO must take this into consideration. Therefore,
we assessed whether the STAT3 KO cells have reduced proliferation compared to wild type in
the growth phase before differentiation. We used the Tag-IT Violet Dye system, a dye that
covalently attaches to proteins in the cell and becomes diluted with each cell division, to track
the proliferation rate of the cells from isolation to confluence. As seen in Figure 3.5, there is no
difference in proliferation of the WT and KO cells during the growth phase.

67

68

Figure 3.5- No difference in proliferation to confluence between WT and KO preadipocytes
A) Cells were labeled with 5µM Tag-It on the day of isolation (grey shaded distribution) and
followed until they reached confluence 6 days later. WT is blue and KO is red. These are
concatenated histograms that contain all 3 biological replicates within each panel. N=3 for each
time point. N.B.: the days indicated here are measured from the date of isolation of the cells, this
is in contrast to other figures where the days are measured starting from induction B) The
relative change in mean fluorescence intensity from the day of isolation to confluence. Data is
expressed as mean ± SEM.
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3.6 STAT3 KO Preadipocytes Have Reduced Proliferation After Induction
The induction phase, also known as the mitotic clonal expansion, is the 48 hours that the
cells are incubated in the induction cocktail. During this time, the cells that were previously
contact-growth inhibited divide 1-3 more times before entering the terminal differentiation phase
(167). Previous work in the 3T3-L1 line indicates that STAT3 is required for the mitotic clonal
expansion (164). To determine if primary brown adipocytes also require STAT3 for the mitotic
clonal expansion, we again used the Tag-IT Violet dilution dye to measure proliferation. As
shown in Figure 3.6, at the end of the Induction Phase (Day 2) there is no difference in loss
relative loss of Tag-IT dye, indicating equal proliferation; however, by Day 4 the WT cells have
undergone a few more rounds of proliferation than the KO. Therefore, we conclude that in the
primary brown adipocyte system, STAT3 can modulate the proliferation of the primary brown
preadipocytes after treatment with the induction cocktail.
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Figure 3.6- STAT3 KO brown adipocytes have reduced proliferation after induction
Cells were stained with 5µM Tag-IT Violet on Day 0 and then immediately induced to
differentiate. A Day 0 WT and KO sample was collected and fixed to provide the baseline
fluorescence. Data is calculated as mean fluorescent intensity of Day 0 divided by the mean
fluorescent intensity of the sample day. N=3. * = p< 0.05, N.S. = not significant. Data is
presented as mean ± SEM.
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3.7 Deletion of STAT3 Leads to Significant Reduction in Differentiation and Brown
Specific Genes
With the Tamoxifen Cre system, the effects of STAT3 on differentiation of primary
brown adipocytes can be studied without the off-target effects of a chemical inhibitor. We
induced STAT3 WT and KO cells and analyzed Day 0 and Day 7 samples for markers of
terminal adipocytes. In Figure 3.7, knockout of STAT3 reduces expression of UCP1 protein to
near undetectable levels, similar to what we observed with the STAT3 inhibitor. Additionally,
PPARγ and CEBPα, two important transcription factors common to both WAT and BAT
differentiation, are reduced. FABP4, a common fat marker, is slightly reduced. Because UCP1 is
so dramatically decreased compared to the other markers of adipogenesis, we wanted to see if
brown-specific markers are affected more by the STAT3 KO than common markers of
adipogenesis. In Figure 3.8, we measured the mRNA expression of brown fat specific or
selective markers and markers common to both WAT and BAT. Interestingly, brown fat markers
are significantly reduced, while the general fat markers are only trending downward in their
expression.
Visually, knockout of STAT3 led to a significant decrease in lipid accumulation
compared to the WT STAT3 samples, as well as an apparent reduced number of cells while still
confluent (Figure 3.9). Together, this data indicates that loss of STAT3 does not prevent the
cells from attempting differentiation, however, full differentiation is suppressed and the
thermogenic program is significantly affected.
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Figure 3.7- KO of STAT3 significantly reduces expression of UCP1
Representative immunoblot of Day 0 and Day 7 brown adipocytes for markers of brown fat and
markers common to all types of fat. N=3.
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Figure 3.8- Expression of brown fat markers are more affected by knockout of STAT3 than
general fat markers
RT-qPCR of Day 7 adipocytes for markers of brown fat and markers common to all types of fat.
* indicate p< 0.05 compared to the wild type marker. Student’s t-test. N=4. Data is expressed as
mean ± SD.
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Figure 3.9- Knockout of STAT3 significantly reduces lipid accumulation
A) Representative plates of Day 7 adipocytes were fixed and stained with Oil-Red O, a dye that
is retained in the neutral triglycerides of adipocyte lipid droplets. B) Day 7 adipocytes were
imaged at 10x magnification, scale bar = 200µm. C) Quantitation of B). Student’s t-test. N=3. *
indicates p< 0.05. Data is presented as mean ± SEM.
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3.8 Tamoxifen is not Responsible for the Defects in Differentiation
While the Tamoxifen Cre system is a powerful tool to isolate the effects of STAT3 on
differentiation of brown adipocytes, one weakness is that only one group receives tamoxifen
while the other receives the ethanol vehicle. Because tamoxifen has been reported to affect
UCP1 expression in-vivo, we wanted to rule out that the effects we see with the STAT3 KO are
due to tamoxifen (168). In Figure 3.10, preadipocytes that contain floxed STAT3, but lack the
Cre Recombinase, were treated with either ethanol or tamoxifen for 48 hours after isolation,
exactly as is done for the STAT3 KO preadipocytes. Figure 3.10A shows that treatment with
tamoxifen does not alter the levels of UCP1 protein, and Figure 3.10B shows that tamoxifen does
not alter the ability of the cells to accumulate lipid. Thus, with these controls, we can conclude
that the effects we see in the STAT3 KO are due to loss of STAT3 and not the tamoxifen
treatment.
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Figure 3.10- Tamoxifen treatment has no affect on brown preadipocytes ability to
differentiate
A) Representative Immunoblot of whole cell lysates from Day 0 or Day 7. The cells were treated
with 1µM 4-OH Tamoxifen for 48 hours after isolation, exactly as for the STAT3 KO, but these
cells lack the Cre Recombinase. N= 3. B) Representative plates of Oil Red O Staining in cells
lacking the Cre Recombinase treated with tamoxifen. N= 3.
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3.9 PPARγ is Less Stable in the STAT3 KO
We have observed that the levels of PPARγ are reduced at Day 7 (Figure 3.7), and if we
increase the exposure time, we can also see that at Day 0 there is already a reduction in PPARγ
levels (Figure 3.4). Since PPARγ is considered a master regulator of adipogenesis, and previous
work indicates that STAT3 is upstream of PPARγ, we wanted to determine if STAT3 is involved
in regulating PPARγ expression. In Figure 3.11A, we analyzed Day 0 mRNA expression of
PPARγ and found no difference, indicating that STAT3 may regulate PPARγ posttranscriptionally. There is a report that PPARγ stability can be regulated by Interferon Gamma
(IFNγ) (169). Specifically, IFNγ recruits ERKs 1 and 2 to phosphorylate PPARγ, which marks
PPARγ for degradation by the proteasome. While we did not measure IFNγ levels in the media,
we did measure expression of a marker of interferon signaling, ISG15, at Day 0 and found it to
be highly up regulated in the STAT3 KO (Figure 3.11B). It should be noted that ISG15
expression is not specific to IFNγ, as other interferons can also increase expression of this gene
(170). Therefore, we wanted to test if PPARγ has a higher turnover rate in STAT3 KO cells, and
if this is due to IFNγ/ERK signaling. In Figure 3.11C we treated Day 1 STAT3 WT and KO
preadipocytes with 10µM MG-132 (Lanes 3 and 4), a proteasome inhibitor, for 8 hours.
Treatment with MG-132 was able to restore levels of PPARγ in the STAT3 KO; however,
treatment with the MEK inhibitor PD0325901 for 8 hours had no affect on PPARγ levels (Lanes
5 and 6), even though the MEK inhibitor did reduce phosphorylation of ERK1/2 (Figure 3.11E).
During the treatment period levels of PPARγ mRNA levels trended downward, but to the same
extent on the WT and KO (Figure 3.12E). These results indicate that PPARγ is undergoing
increased degradation in the absence of STAT3, but it is not likely through the reported
IFNγ/ERK pathway.
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Figure 3.11- PPARγ has increased turnover in the STAT3 KO preadipocytes
A) RT-qPCR of PPARγ from Day 0 preadipocytes. N=3. Student’s t test. B) RT-qPCR of ISG15
from Day 0 preadipocytes. N=3. Student’s t test. Data is presented as the mean ± SD C)
Representative immunoblot of whole cell extracts from Day 1 preadipocytes treated with either
10µM MG132 or 10µM PD0325901 for 8 hours. N=2. TBP is used as a loading control. D)
Densitometry of immunoblot in C). N=2. Data is expressed as mean ± SEM. E) Immunoblot of
two STAT3 WT and KO biological replicates from Day 1 whole cell lysates blotted for
phosphorylated ERK1/2. Cells were treated with vehicle or PD0325901 for 8 hours. TBP is used
as a loading control. F) RT-qPCR of PPARγ from Day 1 STAT3 WT and KO treated with
vehicle or MG132 for 8 hours. N=2. Data is expressed as mean ± SD.
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3.10 Deletion of STAT3 after the Induction Phase does not alter UCP1 levels
Although the STAT3 inhibitor studies (Figure 3.3) suggested that STAT3 was required
only during the induction period, there is the possibility of non-specificity using a STAT3
inhibitor. Using the Tamoxifen-Inducible Cre system, we are able to delete STAT3 at different
times during differentiation and avoid the problem of off target effects. Deletion of STAT3 prior
to induction leads to loss of UCP1 levels and a reduction in PPARγ (Figure 3.12, Lane 1).
However, if tamoxifen is added at Day 2 or Day 5, there is no reduction in UCP1 or PPARγ
protein compared to the WT (lanes 2, 3, 4). This confirms that STAT3 is only required for
differentiation during the induction phase, and is dispensable for UCP1 expression after the
induction phase is complete.
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Figure 3.12- Deletion of STAT3 after the induction phase has no effect on UCP1 protein
levels
Representative immunoblot of Day 7 whole cell extracts. D2= tamoxifen added to WT cells on
Day 2, D5= tamoxifen added to WT cells on Day 5. N=3.
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3.11 pan-JAK Inhibition Suggests that the JAK/STAT Pathway has a Biphasic Response to
Differentiation
Since STAT3 is down regulated after the induction period, and deletion of STAT3 after
induction does not affect total UCP1 amounts, it is possible that the JAK/STAT pathway may be
pro-adipogenic during the induction period and anti-adipogenic after induction. To test this
hypothesis, we treated the preadipocytes with 2µM of Ruxolitinib, a pan-JAK inhibitor, either
during the induction phase (D0-D2), or after the induction phase (D2-D7). In Figure 3.13,
treatment with 2µM of Ruxolitinib during the induction period results in reduced amounts of
UCP1 in the STAT3 WT (Lane 3), which is expected as this should block both STAT3 and
STAT5 signaling. Interestingly, treatment with Ruxolitinib during the terminal differentiation
phase actually up regulated expression of UCP1 in the STAT3 WT (Lane 5). We have seen
before that Ruxolitinib can increase UCP1 expression, but that was in an immortalized system
and treatment improved UCP1 expression regardless of what stage of differentiation the cells
were in (171). This indicates that: 1) The JAK/STAT pathway is either pro-adipogenic or antiadipogenic depending on the stage of differentiation, and 2) that immortalization changes the
cells in an unknown way that removes this biphasic response. Treatment with Ruxolitinib had no
affect on the KO regardless of when the drug was added (Lanes 4 and 6).
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Figure 3.13- Inhibition of JAK shows a biphasic response
Representative Immunoblot of Day 7 lysates from STAT3 WT (Lanes 1, 3, 5) and KO (Lanes 2,
4, 6) cells treated with vehicle or 2µM Ruxolitinib during different periods of the differentiation
time course. The exposure time was adjusted so that Lane 5 was not saturated; WT vehicle (Lane
1) appears to be decreased due to these exposure conditions but are likely not affected. N=2.
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3.12 STAT3 KO Cells Have Increased Apoptosis in the Early Terminal Differentiation
Phase
We noticed that the number of cells on the STAT3 KO plate seemed to become less
numerous as the differentiation time course proceeded, even though the cells start at a similar
density to STAT3 WT cells. While part of this difference may be due to reduced proliferation of
the STAT3 KO cells during the induction phase, we wanted to see if there were any differences
in apoptosis between STAT3 WT and KO during the differentiation time course. In Figure
3.14A and B, we sampled different time points utilizing Annexin V/Propidium Iodide Flow
Cytometry. We saw that the induction cocktail increased Annexin V staining equally in the WT
and KO on Day 2 compared to pre-induction at Day 0. However, by Day 4, the levels of Annexin
V staining decreased in the WT whereas levels doubled for the KO. By Day 7, the levels of
Annexin V in the KO returned to WT levels. The increased Propidium Iodide positive/Annexin
V negative staining seen in the WT and the KO at later time points are likely artifacts of
processing cells as the adipocytes become more fragile and more likely to have a membrane
rupture due to the increased lipid droplet accumulation. As a positive control, we treated WT
Day 0 and Day 4 cells with 500µM H2O2 for 5 hours (Figure 3.14B and C). These results
indicate that there is a defined window during the early terminal differentiation phase where the
KO cells can initiate apoptosis. Not all cells initiate apoptosis, as the plate is still confluent by
Day 7 (Figure 3.9). There is likely a spectrum of response in the STAT3 KO cells. Some cells
may not respond to the induction cocktail and begin differentiation. Other cells respond and are
able to fully differentiate by forming lipid droplets and expressing some UCP1. Most cells
appear to fall in between, differentiating up to a point and then either stalling or initiating
apoptosis.
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Figure 3.14- STAT3 KO have increased apoptosis during the early terminal differentiation
phase
A) Annexin V/Propidium Iodide Flow Cytometry time course for WT and KO STAT3
adipocytes. The graph is a concatenation of 3 biological replicates per time point for both WT
and KO. B) Quantitation of the Apoptosis time course. Two-way ANOVA with Sidak’s multiple
comparison’s tests. * = p< 0.05. N=3 for each sample. Data is presented as the mean ± SEM. C)
Positive controls for Apoptosis assay utilizing 500µM H2O2 for 5 hours. D) Quantitation of C).
One-way ANOVA with Dunnett’s multiple comparison’s test. N.s. = not significant. N=3 for
WT Day 0 and N=2 for WT Day 4. Data is presented as the mean ± SEM.
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3.13 Inhibition of Wnt Ligand Secretion During Induction Rescues the Adipogenic and
Thermogenic Program in STAT3 KO Preadipocytes
We wanted to determine if STAT3 regulates signaling pathways known to be important
during the early stages of adipogenesis. We decided to use an inhibitor/activator screen to see if
we could identify a pharmacological agent that could rescue adipogenesis in the STAT3 KO. We
selected the following three agents for our first screen: IWP2, a general Wnt inhibitor; DAPT, an
inhibitor of the Notch Pathway; and SAG, an agonist for the Hedgehog Pathway. We selected
these three drugs after a literature search indicated that these three pathways (Wnt, Notch, and
Hedgehog) can modulate adipogenesis and that these pathways have been reported to have crosstalk with the JAK/STAT pathway (172-178). We incubated the preadipocytes with these three
drugs starting one day before induction and continuing throughout the full differentiation period.
We found that inhibition of the Notch pathway or activation of the Hedgehog pathway did not
rescue differentiation of STAT3 KO cells. However, treatment with 1µM of IWP2, an inhibitor
of Porcupine (PORCN) in the Wnt signaling pathway, fully restored UCP1 expression in the
STAT3 KO cells (Figure 3.15A, lanes 2 vs. 4). PORCN is an endoplasmic reticulum
intramembrane O-serine palmityltransferase whose function is to add an acyl group to a
conserved serine in all Wnt ligands (179). This acylation is necessary for proper secretion and
signaling of Wnt ligands (145). IWP2 does not affect Wnt signaling from exogenous sources of
Wnt, suggesting that the source of the Wnt that is suppressing STAT3 KO cells are from the cells
themselves and not the media. We also tested another PORCN inhibitor, Wnt-C59, to confirm
that the results are due to inhibition of PORCN and reduce the possibility of off-target effects. As
expected, treatment with 1µM of this second PORCN inhibitor recapitulated the results seen with
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IWP2 (Figure 3.15B). Treatment with IWP2 and Wnt-C59 also restored lipid droplet
accumulation in the STAT3 KO cells (Figure 3.15C).
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Figure 3.15- Inhibition of PORCN rescues STAT3 KO brown adipocytes
A) Representative immunoblot of Day 7 cells from an inhibitor/activator screen for drugs that
can rescue STAT3 KO cells. Cells were treated for 7 days with either 1µM IWP2, 5µM DAPT,
100nM SAG, or DMSO control. N=3. B) Representative immunoblot of Day 7 cells treated with
1µM Wnt-C59 for 7 days. C) 10x micrograph of Oil Red O staining from Day 7 cells treated
with IWP2 or Wnt-C59 for 7 days. Scale bar = 200µm. N=3. D) Whole plate Oil Red O Staining
of Day 7 cells treated for 7 days with Wnt-C59. N=3.
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3.14 STAT3 KO Cells have Reduced Histone H3K27 Acetylation at the UCP1 Promoter
and Enhancer Regions and can be Rescued with IWP2
Epigenetic changes occur during adipogenesis that regulate access to cell-specific genes
involved in the mature functioning brown adipocyte (180). We wanted to determine if STAT3
KO adipocytes have altered histone modifications at the UCP1 enhancer and proximal promoter
regions, and whether rescue with Wnt inhibition can restore those histone modifications. ChIPs
were performed using an antibody to H3K27Ac, a marker of open and active chromatin (181). In
Figure 3.16, STAT3 KO cells have reduced levels of H3K27Ac in the enhancer and proximal
promoter regions of UCP1, and treatment with IWP2 restores this histone modification.
PRDM16 mRNA expression is down 5-fold in the KO, so we also analyzed histone acetylation at
the PRDM16 promoter. Although it failed to reach statistical significance, the same trend can be
seen: STAT3 KO have less acetylation and IWP2 treatment can restore acetylation. The reduced
acetylation is not a global depression as acetylation levels are equivalent between the WT and
KO, and are also unchanged between vehicle and IWP2 treatment conditions. Additionally, we
profiled a site that should not contain acetylated histone. IGX1A is a region in the mouse
genome that is considered a “gene desert” as there are no known transcription start sites within 1
megabase of the region. As expected, histone acetylation is barely above the non-specific IgG
background.
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Figure 3.16- STAT3 KO cells have reduced H3K27Ac levels that can be rescued with IWP2
ChIP of the UCP1 Enhancer and Proximal Promoter regions, PRDM16 promoter, and positive
(Actin Promoter) and negative (IGX1A) controls from Day 5 adipocytes treated with 1µM IWP2
or vehicle from D0-D5. Two-way ANOVA with post-hoc testing compared to the KO H3K27Ac
sample. * = p< 0.05. N=3. Data is presented as the mean ± SEM.
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3.15 Wnt Inhibition is needed only during the Induction Period, showing temporal
correlation with STAT3
We wanted to determine if inhibition of Wnt signaling during the induction period is
sufficient to rescue STAT3 KO preadipocytes. STAT3 KO cells were incubated with IWP2
either during the induction phase (Day 0 to Day 2), after the induction phase (Day 2 to Day 7), or
for the whole period (Day 0 to Day 7). Inhibition of Wnt signaling during the induction period is
necessary and sufficient to rescue UCP1 in STAT3 KO cells, and is unable to rescue UCP1 after
the induction period is completed (Figure 3.17). This result is in agreement with a previous
study that determined that Wnt inhibition increases UCP1 expression in wild-type beige cells
when added during the induction phase (182). Therefore, there is a temporal correlation between
when STAT3 is required, and when Wnt inhibition can rescue STAT3 KO preadipocytes.
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Figure 3.17- IWP2 can only rescue STAT3 KO preadipocyte differentiation when applied
during the induction period
Immunoblot from Day 7 lysates of adipocytes treated with IWP2 during different phases of
differentiation. The time range for IWP2 treatment is given relative to addition of the induction
cocktail. N= 3.
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3.16 β-Catenin Levels are not Down Regulated in the STAT3 KO
Inhibition of the Wnt pathway with IWP2 provides a way to rescue STAT3 KO preadipocytes,
but this alone does not tell us which Wnt pathway is responsible as IWP2 suppresses secretion of
Wnt ligands for both the β-catenin canonical pathways and the non-canonical β-catenin
independent pathways. Previous studies have shown that the canonical β-catenin pathway and
the non-canonical Calcium-Calmodulin/Calcineurin pathway both suppress adipogenesis in 3T3L1 cells (159). Most of the literature to date has focused on the canonical β-catenin pathway in
the suppression of adipogenesis, so we decided to analyze β-catenin levels over the course of
differentiation.
In Figure 3.18A, by the end of the induction phase, β-catenin has been down regulated in
the WT cells but not in the KO. There also appears to be a trend towards increased β-catenin
levels in the KO during the induction period. Surprisingly, by Day 7 β-catenin is still detectable
in the KO cells and is increased approximately 15 fold over the WT (Figure 3.18B and C).
When the mRNA levels of β-catenin are measured at Day 7, we see no difference, indicating that
the down regulation of β-catenin is occurring post-transcriptionally (Figure 3.18D).
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Figure 3.18 -β-Catenin is not down regulated in the STAT3 KO
A) Representative immunoblot of STAT3 WT and KO preadipocytes during the induction phase.
Time is hours after addition of induction cocktail. N=3. B) Representative immunoblot of Day 7
STAT3 WT and KO adipocytes. N=5. C) Densitometry of B). O.D. (A.U.) = Optical Density,
Arbitrary Units. N=5. * = p< 0.05. Student’s t test. Data is presented as mean ± SEM D) RTqPCR of Day 7 STAT3 WT and KO adipocytes for β-Catenin. N=3. N.S.= not significant.
Student’s t test. Data is presented as mean ± SD.
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3.17 STAT3 KO adipocytes have increased Wnt/β-Catenin signaling during the induction
phase
Since β-Catenin levels are not down regulated by the end of the induction phase, this
suggested that there is increased Wnt/β-Catenin Signaling during the induction period.
Measurement of mRNA levels for Axin2, a scaffold protein that is integral to the β-catenin
destruction complex, and Dkk1, a natural antagonist to the Wnt pathway through sequestering of
the co-receptor LRP6, are considered β-catenin regulated genes and are thus used to determine
any differences in Wnt/β-catenin signaling (183, 184). In Figure 3.19, both Axin2 and Dkk1 are
elevated in the STAT3 KO, confirming that the canonical Wnt pathway is elevated in the STAT3
KO adipocytes.
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Figure 3.19- Wnt/β-catenin signaling is elevated during induction phase in STAT3 KO
RT-qPCR of Day 1 STAT3 WT and KO adipocytes profiled for β-catenin regulated genes Axin2
and Dkk1. N=3. * = p<0.05. Student’s t-test. Data is presented as mean ±SD.
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3.18 Wnt Ligands 3a, 1, and 10b are elevated in STAT3 KO adipocytes during the
induction phase
Now that we have established increased canonical Wnt/β-Catenin Signaling, we wanted
to determine if there is any increased expression in Wnt ligands in the STAT3 KO adipocytes.
Recall from Figure 3.15 that the Wnt ligand secretion inhibitor IWP2 is able to rescue STAT3
KO adipocytes. As IWP2 only blocks Wnt signaling from endogenous sources of Wnt ligands,
this suggested that the KOs may have increased synthesis and secretion of Wnt ligands during
the induction phase. In Figure 3.20, mRNA levels of Wnts 1, 3a, and 10b were measured. All
three signal through the canonical Wnt pathway and all three are elevated; in the case of Wnt3a
the mRNA is up regulated in the STAT3 KO 50 fold.
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Figure 3.20- Canonical Wnt/β-catenin ligands are up regulated during the induction phase
in STAT3 KO adipocytes
RT-qPCR of Day 1 STAT3 WT and KO adipocytes for Wnt ligands that signal through the
canonical β-catenin pathway. N=3. * = p<0.05. Student’s t-test. Data is presented as mean ±SD.
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3.19 The Canonical β-Catenin Pathway is responsible for suppression of differentiation in
STAT3 KO Brown Preadipocytes
Previous studies have established that the canonical β-catenin pathway and the noncanonical Calcium-Calmodulin/Calcineurin pathway suppress adipogenesis in 3T3-L1 cells
(159). Since inhibition of Porcupine is a pan-Wnt inhibitor, we wanted to determine which
pathway or pathways were responsible for suppression of UCP1 in STAT3 KO adipocytes. We
selected IWR1-endo to target the canonical β-catenin pathway; the mechanism of action is
through stabilization of Axin2, a scaffold protein of the β-Catenin destruction complex (185) .
For the Calcium-Calmodulin/Calcineurin pathway, we selected FK506, an immunosuppressant
that binds to FK506 Binding Protein (FKBP), which allows for FKBP to bind an inactivate
calcineurin (186).
Treatment with 5µM of the β-catenin inhibitor IWR1-endo resulted in full rescue of
UCP1 protein levels (Figure 3.21A Lanes 2 vs 8). The Calcineurin inhibitor FK506 (10ng/mL)
produced a slight increase in UCP1 levels, which was statistically insignificant. Additionally,
IWR1-endo rescued lipid accumulation in the STAT3 KO, whereas FK506 did not (Figure 3.21
C-E). We also profiled more brown fat selective/specific and general fat markers by RT-qPCR.
In Figure 3.22, there is robust rescue of brown fat markers such as CIDEA, PRDM16, and
PPARα. Interestingly, the general fat markers were more mixed; some markers were down in the
STAT3 KO and were rescued by Wnt/β-Catenin inhibition, others appear to be unchanged in the
WT versus the KO samples.
Since Wnt inhibition can rescue the expression of UCP1 and other aspects of adipocyte
differentiation, we wanted to profile the other defects we have seen in the STAT3 KO to
determine if the Wnt/β-Catenin pathway is involved. In Figure 3.23, we analyzed Annexin
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V/Propidium Iodide staining of Day 4 WT and KO STAT3 adipocytes. Treatment with IWP2
and IWR1-endo, but not FK506, is sufficient to reduce Annexin V staining. This indicates that
the Wnt/β-catenin pathway is responsible for the increased marker of apoptosis we see in the
STAT3 KO cells.
We also measured the proliferation of the cells treated with the inhibitors to determine if
the proliferation defect seen in the STAT3 KO could be rescued by Wnt inhibitions. Day 4
adipocytes were analyzed with the dilutional dye Tag-IT in the presence of the inhibitors or
vehicle (Figure 3.24). The proliferation defect was unaffected by treatment with the Wnt
inhibitors, indicating that the proliferation defect is independent of the increased Wnt signaling
in the STAT3 KO.
As a positive control, we took STAT3 KO Day 1 adipocytes treated with the inhibitors
and profiled expression of Axin2. In Figure 3.25, Axin2 levels are decreased in the IWP2 and
IWR1-endo conditions, but not in the FK506 condition. FK506 targets a non-canonical β-catenin
independent pathway so the unchanged expression of Axin2 is as expected.
To confirm our results that it is the β-catenin pathway that is specifically involved, we
selected a second β-catenin inhibitor, XAV939. In Figure 3.26A-C, treatment with 1µM of
XAV939 was also able to rescue UCP1 protein levels, decrease β-Catenin levels, and restore
lipid accumulation in the STAT3 KO cells. Conversely, we inhibited GSK3β in WT cells using
10µM CHIR99021 for just the induction period (D0-D2). It is well known that inhibiting GSK3β
can stabilize β-catenin levels and suppress adipogenesis in-vitro, and here we see no exception
(187). In Figure 3.26D-F, GSK3β inhibition results in total suppression of differentiation in the
WT STAT3 brown adipocytes and also stabilizes β-catenin levels out to Day 7. Altogether, these
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results indicate that Wnt/β-catenin inhibition is sufficient to restore differentiation in STAT3 KO
cells.
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Figure 3.21- β-catenin pathway inhibitors rescue STAT3 KO brown adipocytes
A) Representative immunoblot of Day 7 WT and KO STAT3 brown adipocytes treated with
different inhibitors or vehicle for 7 days. N=4-5 for each treatment. B) Densitometry of A). O.D.
(A.U.) = Optical Density (Arbitrary Units). N=4-5 for each treatment. * = p< 0.05 compared to
KO DMSO. One-Way ANOVA with Sidak Multiple Comparison Test. Data is presented as
mean ± SEM. C) 10x micrographs of Oil Red O staining of Day 7 WT and KO STAT3 brown
adipocytes. Scale bar = 200µm. D) Quantitation of percent of field positive for Oil Red O stain in
C). N=3-4 per treatment. * = p< 0.05 compared to KO DMSO. One-Way ANOVA with Sidak
Multiple Comparison Test. Data is presented as mean ± SEM. E) Whole Plate Oil Red O staining
of Day 7 WT and KO STAT3 brown adipocytes.
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Figure 3.22- RT-qPCR analysis of Wnt inhibitors
Day 7 STAT3 WT and KO Cells were treated with the Wnt inhibitors for 7 days or vehicle. RTqPCR was performed on various targets important in brown- and general-adipocyte
development. N=4. * = p< 0.05 compared to KO DMSO. One-Way ANOVA with Sidak’s
Multiple Comparison Tests. Data is presented as mean ± SD. Tbp was used as a loading control.
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Figure 3.23- Treatment with Wnt inhibitors reduces Annexin V staining in the KO brown
adipocytes
A) Flow Cytometry Annexin V/Propididum Iodide of Day 4 primary cells treated with the Wnt
inhibitors or vehicle for 4 days. Each panel is a concatenation of three independent biological
replicates. B) Quantitation of A). One-Way ANOVA with Sidak’s Multiple Comparison Test.
* = p< 0.05. N=3. Data is presented as mean ± SEM.
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Figure 3.24- Wnt inhibition fails to rescue proliferation defect in STAT3 KO
Tag-IT assay of Day 4 STAT3 WT and KO adipocytes treated with the Wnt inhibitors. N=3. * =
p<0.05, compared to KO DMSO. N=3. One-way ANOVA. Data is presented as mean ±SEM.
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Figure 3.25- Canonical Wnt inhibitors block β-catenin signaling
RT-qPCR of Day 1 STAT3 KO adipocytes treated with the Wnt inhibitors or vehicle. N=4. * =
p<0.05. One-way ANOVA. Data is presented as mean ±SD.
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Figure 3.26- XAV939, a second β-catenin inhibitor, rescues STAT3 KO while a GSK3β
inhibitor, CHIR99021, blocks differentiation in WT STAT3 brown adipocytes
A) Representative immunoblot of Day 7 STAT3 WT and KO cells treated for 7 days with 1µM
XAV939 or vehicle. N=2. B) Oil Red O micrographs of Day 7 STAT3 WT and KO cells treated
for 7 days with XAV939 or vehicle. 10x magnification, scale bar = 200µm. N= 3. C) Whole
plate Oil Red O of cells treated with XAV939 for 7 days or vehicle. N=3. D) Representative
immunoblot of Day 7 STAT3 WT cells treated only during the induction with 10µM CHIR99021
or vehicle. N=3. E) Whole plate image of Day 7 WT STAT3 cells treated with CHIR99021 or
vehicle. N=3. F) Oil Red O micrographs of Day 7 WT STAT3 cells treated with CHIR99021 or
vehicle. 10x magnification, scale bar = 200µm. N=3.
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3.20 Knockdown of β-Catenin Before Induction Fully Rescues UCP1 Levels
So far we have demonstrated that inhibitors to the Wnt/β-catenin pathway are able to
rescue adipogenesis in the STAT3 KO cells. Even though we have targeted different aspects of
the pathway with different drugs, there is still a small chance that these inhibitors could be doing
something else to the STAT3 KO to effect rescue independent of β-catenin. Therefore, the
definitive test that it is the inability to suppress β-catenin that is causing the block in
differentiation is to knockdown β-catenin through RNA interference.
48 hours before induction, we transfected either non-targeting control siRNA or β-catenin
specific siRNA and let the transfection proceed for 2 days. When the transfection was complete,
the cells were either induced to differentiate, or Day 0 mRNA was collected for β-catenin
knockdown efficiency analysis. In Figure 3.27A, we saw that the siRNA was effective in
reducing levels of β-catenin approximately 20 fold compared to the non-targeting siRNA. In
Figure 3.27B, the levels of β-catenin in the β-catenin siRNA STAT3 KO sample are still
undetectable at Day 7 compared to control siRNA STAT3 KO (Lanes 2 and 4). Additionally, we
see full recovery of UCP1 in the STAT3 KO where β-catenin is absent. With these results,
combined with the Wnt inhibitor studies, we can confidently conclude that the block in
adipogenesis in the STAT3 KO adipocytes is singly due to the inability to down regulate βcatenin during the induction phase and that full restoration of the adipogenic and thermogenic
program can be rescued in primary Myf5+ brown adipocytes by blocking Wnt/β-catenin.
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Figure 3.27- Knockdown of β-catenin can fully rescue UCP1 in the STAT3 KO brown
adipocyte
A) Day 0 STAT3 WT and KO samples were collected and analyzed by RT-qPCR for β-catenin
knockdown efficiency. N=3. * = p< 0.05. Student’s t test. Data is presented as mean ± SD. B)
Representative immunoblot of Day 7 STAT3 WT and KO Adipocytes. N=2.
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3.21 Beige Cells also Require STAT3 Prior to Induction and can be Partially Rescued with
Wnt Inhibition
The results so far have all been in the Myf5+ lineage of thermogenic adipocytes.
However, as stated in the introduction, beige cells likely have more human relevance as the
UCP1+ adipocytes in humans are Myf5- (77, 81). Therefore, using the results generated in the
Myf5+ lineage, we wanted to determine if STAT3 is also required for beige development, is it
also only required during the induction period, and can Wnt inhibition also rescue STAT3 KO
beige adipocytes.
The SVF from the inguinal fat pads from 1-month-old mice was isolated and STAT3 was
deleted using tamoxifen in an identical fashion to the Myf5+ cells. In Figure 3.28A, we
performed a knockout time course where we either knocked out STAT3 prior to induction or at
Days 2 and 5 after induction. In agreement with the Myf5+ cells, STAT3 is required for UCP1
expression and must be present during the induction period. Deletion of STAT3 after the
induction period also has no deleterious effect on UCP1 protein levels, and if anything, deleting
STAT3 after induction seems to improve UCP1 levels. Also, we see the levels of β-catenin are
elevated in the STAT3 KO beige cells compared to the WT cells, just as it was for the Myf5+
cells.
In Figure 3.28B, we treated the STAT3 WT and KO cells with the Wnt inhibitors. We
used the same treatment conditions as we did for the Myf5+ cells. Interestingly, while IWP2 and
IWR1-endo can increase UCP1 in the STAT3 KO cells, the rescue is not as robust as in the
Myf5+ cells.
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Figure 3.28 Beige cells also require STAT3 during the induction period, but Wnt inhibition
is not as robust
A) Representative immunoblot of Day 7 STAT3 WT and KO beige cells. D2= Tamoxifen added
to WT on Day 2, D5= Tamoxifen added to WT on Day 5. N=3. B) Representative immunoblot
of Day 7 STAT3 WT and KO beige cells treated for 7 days with the indicated inhibitor. N=2.
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3.22 Pilot In-Vivo Beiging Study Shows Equal Induction of UCP1 in the STAT3 WT and
KO animals
We were unable to generate any viable pups from a Myf5+ promoter driven Cre, Floxed
STAT3 animal. Because our Tamoxifen Cre mouse has Cre Recombinase ubiquitously expressed
in every tissue, we were hesitant to attempt to knockout STAT3 in the entire adult animal. We
decided to attempt a pilot study where we orally gavaged three 8-week-old mice once a day for
five days at a dose of 5mg/20g body weight. One mouse died within a week of administration of
the tamoxifen, while the other two mice were viable. We waited four weeks with the remaining
two mice to allow tamoxifen to clear the system, since it is reported that tamoxifen can induce
browning in the inguinal fat pad (168). For one mouse, we injected I.P. once daily a 1mg/kg
body weight dosage of CL316,243, a β3 agonist, to induce browning of the inguinal fat pads for
a total of 7 days. The other mouse received an equivalent dosage of PBS. As controls, we took
two mice that had not been gavaged with tamoxifen and injected one with CL316,243 and the
other with PBS at the same dosage as the KO mice. We harvested the fat pads and ran
immunoblots for STAT3 and UCP1. In Figure 3.29, the tamoxifen was effective in knocking
down STAT3 expression (Lanes 2 and 4), however, the mice still induced UCP1 protein levels to
an equal extent to the WT controls (Lanes 3 and 4). The PBS mice as expected show no evidence
of browning.

119

Figure 3.29- Deletion of STAT3 in inguinal fat pad of 8 week old mice appears to not affect
UCP1 induction with the β3 agonist CL316,243
Immunoblot of mouse inguinal pads from WT and KO STAT3 mice treated once per day for 7
days with 1mg/kg CL316,243 by I.P., or with PBS control. N=1 mouse for each condition.
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3.23 Primary Tyk2 KO cells Differentiate Normally
Previously, our lab had investigated the role of Tyk2 in brown adipocyte differentiation .
Most of the cell work involved SV40 immortalized Tyk2 WT and KO cells. We decided to
continue the project utilizing primary cells. However, in the primary cell system, we were unable
to recapitulate our prior results. We isolated SVF from interscapular fat pads of newborn mice
from either a Tyk2 WT or total Tyk2 KO line. We grew them to confluence and induced them to
differentiate and analyzed the cells by RT-qPCR. In Figure 3.30, the expression levels of UCP1
and CIDEA are not different between the Tyk2 WT and Tyk2 KO lines.
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Figure 3.30- Primary Tyk2 KO brown adipocytes have equal UCP1 and CIDEA expression
to the WT
RT-qPCR of Day 6 Tyk2 WT and KO adipocytes. N=4. Data is presented as mean ± SD. 18S
rRNA was used as a loading control.
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3.24 Tyk2 KO animals Appear to Beige Normally under β3 Agonist Stimulation
We also attempted to determine if Tyk2 is required for beiging under stimulation by the
β3 agonist CL316,243. We treated WT and KO Tyk2 mice to once daily I.P. injections of either
PBS or 1mg/kg body weight CL316,243 for 7 days and then harvested the inguinal fat pad for
analysis by RT-qPCR for UCP1 expression. In Figure 3.31, the WT and the KO Tyk2 animals
induced equal expression of UCP1 under stimulation from the β3 agonist.
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Figure 3.31- Induction of UCP1 mRNA by CL316,243 in Tyk2 KO mice appear to be
normal
RT-qPCR for UCP1 expression in the inguinal fat pads of mice treated with either PBS or
1mg/kg CL316,243 once a day for 7 days by I.P. injection. N=2 mice per group. 18S was used as
a loading control. Data is presented as mean ± SD; normalized to Tyk2 WT control.
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3.25 Immortalization of STAT3 Preadipocytes Appears to Remove the Requirement for
STAT3 in Differentiation
Use of primary cells allows for robust differentiation of adipocytes and expression of
UCP1; however there are downsides. The primary cells only become available when there are
newborn pups available, which makes the frequency of obtaining samples difficult to predict;
therefore, a large breeding colony has to be maintained to ensure constant supply of primary
cells. Additionally, primary cells lose their ability to differentiate the longer they are in culture.
In our hands, the WT cells start to significantly lose their ability to express UCP1 after more than
one week in culture (data not shown). For these reasons, many investigators create cell lines of
adipocytes through immortalization using Murine Stem Cell Virus containing the SV40 Large T
Antigen. Our prior work in adipocytes utilized immortalized lines, and we began the project with
the intent to create an immortalized STAT3 line. However, as Figure 3.32 shows, once the cells
are immortalized, the difference seen in UCP1 mRNA expression levels in primary cells is lost.
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Figure 3.32- UCP1 mRNA expression appears to be equal in SV40 immortalized WT and
KO STAT3 brown adipocytes
RT-qPCR of UCP1 mRNA in Day 7 WT and KO STAT3 immortalized brown fat cells. N=2.
Data is expressed as mean ± SD. Tbp was used as a loading control.
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3.26 Mitochondrial STAT3 Levels Decrease During the Induction Period and Remained
Depressed Throughout the Terminal Differentiation Phase
Previous work in our lab has identified that STAT3 can localize to the mitochondria,
where it can affect functions such as ROS production, ETC activity, and binding to Cyclophilin
D, part of the Mitochondrial Permeability Transition Pore (MPTP) (188-190). Therefore, we
wanted to determine whether STAT3 localizes to the mitochondria in brown adipocytes and how
its levels change during differentiation. In Figure 3.33, STAT3 rapidly exits the mitochondria
during the induction phase and appears to stay depressed throughout the terminal differentiation
phase. This rate of loss from the mitochondria appears to be more rapid than the reduction in
cytosolic fractions. In contrast, levels of STAT1 in the mitochondria appear to be relatively
unchanged during the time course.
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Figure 3.33- STAT3 rapidly exits the mitochondria during brown adipocyte differentiation
Representative immunoblot of cytosolic and mitochondrial fractions from primary adipocytes at
the indicated time points along the differentiation time course. N=2.
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Chapter 4: Discussion
We have shown for the first time that STAT3 is necessary for differentiation of primary
brown adipocytes. Loss of STAT3 leads to a more than 10 fold loss of UCP1 and CIDEA, and 5
fold reduction in PRDM16 and PPARα expression (Figure 3.8). Interestingly, the general fat
genes show more variability; this is a result we have seen before in a STAT3 shRNA
immortalized cell system (139). One interpretation is that STAT3 may have brown fat specific
effects in addition to its role in the general adipogenic program; our previous results did show
that STAT3 physical interacts with and stabilizes PRDM16, which lends support to this model.
However, another equally valid model is that the cells are encountering a decision point early in
the differentiation program before the thermogenic program is fully initiated so that cells can
gain access to the chromatin of brown fat specific genes. Figure 3.16 showed that at Day 5,
Histone H3K27Ac is decreased in the STAT3 KO at the UCP1 promoter and enhancer regions.
We have attempted to ChIP the UCP1 promoter and enhancer before Day 5, but we were unable
to detect any significant histone acetylation (data not shown). The reduction is histone
acetylation would presumably make access to the promoter and enhancer binding sites for
transcription factors like PPARγ, PPARα, PGC1α, and PRDM16 much more difficult. Also
supporting this model is the increase in apoptosis seen at Day 4 in the STAT3 KO (Figure 3.14).
The increased apoptosis could be due to conflicting signals in the cells. The STAT3 KO cells are
clearly attempting to differentiate as markers of adipocytes are not present in Day 0 lysates, but
present in Day 7 and show little difference (Figure 3.4). However, if they are also receiving
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suppressive signals, for example from the Wnt/β-Catenin pathway, the cells undergo a stochastic
decision point to either halt differentiation and remain in a quasi-adipocyte state, or initiate
apoptosis.
Since STAT3 has first been studied in the 3T3-L1 system, it has been hypothesized that
STAT3 only functions during the induction phase in in-vitro differentiation of adipocytes .
However, to our knowledge, no one has directly tested that hypothesis through either
pharmacological inhibition time courses or gene deletion time courses. We therefore believe we
are the first to confirm this hypothesis. It is also interesting that the JAK/STAT pathway appears
to have a biphasic response during differentiation of brown fat. In Figure 3.13, Ruxolitinib
increased UCP1 protein levels in WT STAT3 cells over the vehicle control. This effect has been
seen before in immortalized systems of brown and beige (171). However, the decrease with
Ruxolitinib during the induction phase is a new finding, and not surprising given the role that
STAT3 and STAT5 play in adipogenesis. What complicates these findings are in-vivo studies
that show that cytokines like IL-6, which signal in part through STAT3, generally increase UCP1
levels (191). It could be that the in-vitro system is exposed to cytokines in the serum or released
from the cells themselves that suppress full expression of UCP1, while other cytokines that are
not present in-vitro but are present in-vivo would always be pro-thermogenic and adipogenic no
matter what phase of development the tissue is in. Another explanation is the in-vitro model of
adipogenesis fails to adequately recapitulate what is seen in-vivo, which is certainly possible.
This is concerning about the applicability of our findings to in-vivo models, however, this pilot
study has some caveats. First, we do not know which cells in the tissue actually were knocked
out with STAT3. Some cells may not have been exposed to tamoxifen, and these cells were
enough to produce UCP1 under β3 agonism. Tissue immunofluorescence for STAT3 after
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addition of tamoxifen would determine what percentage of cells in the tissue are STAT3 KO.
Additionally, we may have deleted STAT3 at a point in the development of the tissue where
STAT3 is no longer required. We unfortunately were unable to create a tissue specific knockout
line of STAT3 using an early acting Cre. While another STAT3 adipose specific knockout
mouse exists, it is driven by the aP2 promoter- a terminal marker of adipocytes. If our in-vitro
results do correlate to an in-vivo system, then by the time aP2 is turned on, STAT3 has already
fulfilled its function in adipogenesis and any effects seen are defects in the functioning of mature
adipocytes. Currently, other than Myf5 Cre, with which we failed to generate any viable pups,
there is no early acting Cre that would be limited to BAT that could be used to test the in-vivo
role of STAT3 in brown adipose development.
Until now the function of STAT3 during the induction phase was not well characterized.
There was a report that PPARγ was downstream of STAT3 and STAT3 KO cells can be rescued
by application of a PPARγ agonist. Our protocol involves treating the cells with rosiglitazone, a
PPARγ agonist, during the induction period. We have attempted to leave rosiglitazone in the
cells for the entire 7 days, but we have seen that most replicates are unable to be rescued by
continuous PPARγ agonism. In fact, our beige in-vitro system involves leaving rosiglitazone in
the entire 7 days to maximize UCP1 expression, but rosiglitazone still failed to rescue UCP1
levels in the beige cells.
With our results, we now show that the major function of STAT3 during in-vitro
differentiation is to suppress β-catenin levels. Through both pharmacological inhibition and
knockdown studies, we were able to completely restore UCP1 protein levels, and mRNA
expression of other markers of brown adipocytes like PRDM16 and CIDEA. Therefore, we
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conclude that the single block to differentiation of STAT3 KO primary brown adipocytes is the
inability to suppress β-catenin.
In hindsight, it is not surprising that STAT3 would be involved in cross talk with βcatenin; there are multiple papers in the literature describing cross talk between β-catenin and
STAT3 (192, 193). However our results are novel, because research to date has usually shown
STAT3 and Wnt co-operatively functioning rather than in opposition (178, 193-195). Why there
is this difference between STAT3 and Wnt interaction in adipocytes versus other systems
requires further study.
Another interesting finding is that STAT3’s regulation of β-catenin is posttranscriptional. β-catenin mRNA amounts at Day 7 are not different between the STAT3 WT and
the STAT3 KO (Figure 3.18). This is likely due to increased synthesis and secretion of Wnt
ligands, especially Wnt3a, as the presence of Wnt ligands stabilizes β-catenin (Figure 3.20).
That β-catenin is still elevated at Day 7 indicates that Wnt ligands are still present in the STAT3
KO. There are multiple reports describing long-term regulation of Wnt ligand expression in
adipocytes. Specifically, EZH2, a metyltransferase that is part of the polycomb repressor
complex 2 (PRC2), methylates Histone H3 K27 in the promoters of Wnt ligands as
differentiation progresses, which results in silencing of those genes (160, 196). This could
indicate that in the absence of STAT3, the long-term suppression of Wnt signaling is affected.
The elevated β-catenin could also be the result of suppressed proteasomal degradation. It is
known that STAT3 can crosstalk with GSK3β, which is part of the β-catenin destruction
complex, and they can appear to regulate each other (197, 198). Additionally, a recent report
determined that STAT3 interacts with and stabilizes an E3 Ubiquitin Ligase, SIAH1 (199). The
stabilized SIAH1 then leads to increased proteasomal degradation of β-catenin.
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Our findings also show that STAT3 is required for full UCP1 expression in beige cells,
and indeed, KO of STAT3 also led to increased β-catenin in the beige cells (Figure 3.28).
However, rescue with Wnt inhibition was only partial. There are several possible explanations
here. The first is that the mechanism of STAT3 in beige fat is slightly different and does not
depend as much on surpressing β-catenin. Another explanation is that the inhibitors are not
adequate in beige fat and knockdown or deletion of β-catenin is necessary for full restoration.
Additionally, we are isolating the SVF from one month old mice for beige studies and newborn
pups for the Myf5+ studies. This difference in isolation protocols exists because at birth the
Myf5+ interscapular fat pad is present, while the inguinal fat pad is not. We must wait for the fat
pad to develop before we can harvest and adequate number of preadipocytes for experiments. It
is possible that the Wnt pathway plays a stronger role in suppression of differentiation in the
younger cells.
Immortalization of primary brown adipocytes removed all differences between the WT
and KO STAT3 cells, which is what necessitated the use of primary cells. One explanation is that
the β-catenin pathway is suppressed or bypassed in SV40 immortalize cells. However, that is not
the case. The explanation is that immortalization affects the WT more than the KO. When the Ct
values of primary and immortalized lines are compared, we see that the Ct value increases in the
WT, but remains unchanged in the KO. Immortalization therefore negatively affects the WT to
the point that it differentiates comparably to a primary KO STAT3 cell.
Finally, the inability to replicate the results in the Tyk2 primary system is disappointing.
We have no explanation as to why the results were unable to be replicated. The Tyk2 KO mice
are knockout from conception, so it cannot be that the cells have passed a cell fate point where
Tyk2 is no longer needed. One possible explanation is that immortalization may render Tyk2
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more important than in primary cells. As stated above, immortalized WT cells have a reduced
ability to differentiate. We use a retrovirus in our immortalization protocol and we have found
that after immortalization, ISG15, a marker of interferon signaling, is elevated in immortalized
cells compared to primary cells (data not shown). It could be that Tyk2 is needed to attenuate this
“inflammatory” signaling. It is known that interferons can suppress adipogenesis (200, 201). The
suppression of this interferon response in brown adipocytes seems to be through PRDM16 (202).
We have published that deletion of Tyk2 can lead to reduction in PRDM16, but perhaps there is
more complexity to this regulation than is currently understood.
We propose that the function of STAT3 is to repress expression of select Wnt ligands
during the induction phase of adipogenesis. Our model is presented as Figure 4.1. Once the cells
are induced to differentiate, STAT3 is activated through phosphorylation and translocates to the
nucleus, where through either direct or indirect means leads to repression of Wnt ligand
expression. Loss of STAT3 relieves that suppression, leading to increased expression and
secretion of Wnt ligands−particularly Wnt3a which was 50 fold up regulated. The increased Wnt
ligands signal in an autocrine/paracrine manner leading to stabilization and nuclear translocation
of β-catenin. β-catenin then suppresses the expression and activity of transcription factors
important for adipogenesis and the thermogenic program, such as PPARγ, CEBPα, PRDM16,
and PGC1α.
Future work in understanding how STAT3 regulates adipogenesis will require adequate
in-vivo models to confirm that this STAT3/Wnt/β-catenin regulatory pathway is important in the
development of brown and beige adipose tissue. This can be accomplished through adipose
tissue selective STAT3 KO animals treated with either Wnt inhibitors, or by combining the
STAT3 KO animals with a targeted knockout of PORCN, the Wnt ligand acylating enzyme.
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Additionally, how STAT3 regulates Wnt ligand expression is unknown. A pilot in-silico analysis
of the Wnt3a promoter identified putative STAT3 binding motifs within 1000bp of the
transcription start site (data not shown). Finally, more work is required in the primary beige exvivo system to determine if the Wnt suppression mechanism is not conserved in this lineage.
The data presented here advance our understanding of how the JAK/STAT pathway, and
STAT3 in particular, regulates brown adipogenesis. While still in the pre-clinical stages,
methods to increase BAT mass in humans holds potential as an adjunct treatment of obesity,
when combined with diet and exercise. Additionally, increased BAT mass in rodents led to better
glucose control while on a high fat diet; therapies to increase BAT mass could also be used in the
treatment of T2D. Targeted activation of STAT3 at the proper time point in development of these
adipocytes, or inhibition Wnt signaling could be one treatment avenue towards increasing
UCP1+ fat tissue in humans.
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Figure 4.1- Model of STAT3 Suppressing β-Catenin in Brown Adipogenesis
When the preadipocytes are induced to differentiate, STAT3 is activated and through either
direct or indirect means inhibits the expression of select Wnt ligands, leading to reduction in
Wnt/β-Catenin Signaling. The resulting suppression of β-Catenin levels leads to promotion of
adipogenesis.
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